Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alzheimer Disease | 622 | 2024 | 2005 | 54.800 |
Why?
|
Aging | 307 | 2023 | 1630 | 33.070 |
Why?
|
Brain | 310 | 2023 | 1726 | 26.800 |
Why?
|
Cognition Disorders | 234 | 2023 | 1032 | 25.980 |
Why?
|
Cognitive Dysfunction | 188 | 2024 | 969 | 25.750 |
Why?
|
Cognition | 224 | 2023 | 1314 | 21.870 |
Why?
|
Aged, 80 and over | 673 | 2024 | 4930 | 21.020 |
Why?
|
Aged | 750 | 2024 | 9620 | 17.680 |
Why?
|
Dementia | 110 | 2024 | 527 | 17.250 |
Why?
|
Male | 797 | 2023 | 15851 | 14.630 |
Why?
|
Humans | 1098 | 2024 | 29815 | 14.480 |
Why?
|
Female | 796 | 2023 | 16412 | 14.260 |
Why?
|
Neuropsychological Tests | 233 | 2023 | 1270 | 12.550 |
Why?
|
Longitudinal Studies | 223 | 2023 | 1462 | 10.890 |
Why?
|
Genetic Predisposition to Disease | 94 | 2022 | 433 | 10.030 |
Why?
|
Cohort Studies | 228 | 2023 | 1952 | 9.630 |
Why?
|
Amyloid beta-Peptides | 100 | 2023 | 302 | 9.190 |
Why?
|
Parkinsonian Disorders | 36 | 2023 | 222 | 8.390 |
Why?
|
Apolipoproteins E | 76 | 2023 | 235 | 7.860 |
Why?
|
Apolipoprotein E4 | 67 | 2023 | 233 | 7.780 |
Why?
|
Genome-Wide Association Study | 117 | 2023 | 298 | 7.730 |
Why?
|
Polymorphism, Single Nucleotide | 95 | 2022 | 298 | 6.560 |
Why?
|
Memory | 56 | 2021 | 323 | 6.470 |
Why?
|
tau Proteins | 72 | 2023 | 213 | 6.260 |
Why?
|
Neurofibrillary Tangles | 63 | 2023 | 189 | 6.200 |
Why?
|
Risk Factors | 161 | 2023 | 2465 | 5.920 |
Why?
|
Disease Progression | 95 | 2022 | 812 | 5.770 |
Why?
|
Neurodegenerative Diseases | 20 | 2022 | 117 | 5.610 |
Why?
|
Motor Activity | 30 | 2021 | 372 | 5.480 |
Why?
|
DNA Methylation | 27 | 2023 | 127 | 5.430 |
Why?
|
Cerebral Infarction | 30 | 2023 | 154 | 5.410 |
Why?
|
Nervous System Diseases | 14 | 2023 | 150 | 5.280 |
Why?
|
Independent Living | 44 | 2023 | 285 | 5.250 |
Why?
|
Autopsy | 73 | 2023 | 338 | 5.200 |
Why?
|
Memory Disorders | 39 | 2020 | 177 | 5.170 |
Why?
|
Hippocampus | 51 | 2022 | 285 | 5.100 |
Why?
|
Disabled Persons | 18 | 2023 | 129 | 4.990 |
Why?
|
Activities of Daily Living | 45 | 2023 | 507 | 4.940 |
Why?
|
Educational Status | 56 | 2023 | 297 | 4.870 |
Why?
|
Neurons | 48 | 2022 | 380 | 4.800 |
Why?
|
Prefrontal Cortex | 24 | 2023 | 152 | 4.690 |
Why?
|
Plaque, Amyloid | 50 | 2023 | 146 | 4.530 |
Why?
|
Lewy Bodies | 33 | 2023 | 198 | 4.520 |
Why?
|
Cerebrovascular Disorders | 23 | 2023 | 139 | 4.450 |
Why?
|
Cognitive Reserve | 16 | 2022 | 38 | 4.300 |
Why?
|
Memory, Episodic | 29 | 2023 | 120 | 4.250 |
Why?
|
Geriatric Assessment | 29 | 2021 | 221 | 4.230 |
Why?
|
TDP-43 Proteinopathies | 22 | 2023 | 105 | 4.190 |
Why?
|
Health Literacy | 18 | 2023 | 105 | 4.140 |
Why?
|
Genotype | 74 | 2023 | 399 | 4.120 |
Why?
|
Residence Characteristics | 21 | 2021 | 216 | 4.060 |
Why?
|
Magnetic Resonance Imaging | 67 | 2023 | 1247 | 4.030 |
Why?
|
Prospective Studies | 84 | 2023 | 1823 | 3.990 |
Why?
|
Decision Making | 23 | 2023 | 227 | 3.930 |
Why?
|
Proteomics | 23 | 2023 | 93 | 3.920 |
Why?
|
Cerebral Cortex | 22 | 2022 | 196 | 3.900 |
Why?
|
Follow-Up Studies | 85 | 2021 | 1859 | 3.840 |
Why?
|
Nerve Tissue Proteins | 23 | 2022 | 175 | 3.660 |
Why?
|
Transcriptome | 27 | 2022 | 84 | 3.600 |
Why?
|
Parkinson Disease | 34 | 2023 | 1184 | 3.550 |
Why?
|
Cognitive Aging | 14 | 2021 | 81 | 3.430 |
Why?
|
Depression | 27 | 2021 | 472 | 3.390 |
Why?
|
Age Factors | 74 | 2021 | 853 | 3.390 |
Why?
|
Middle Aged | 176 | 2021 | 9960 | 3.310 |
Why?
|
Cerebral Amyloid Angiopathy | 18 | 2023 | 118 | 3.220 |
Why?
|
Proportional Hazards Models | 49 | 2022 | 346 | 3.200 |
Why?
|
Exercise | 21 | 2023 | 474 | 3.140 |
Why?
|
United States | 75 | 2024 | 2344 | 2.950 |
Why?
|
Membrane Proteins | 19 | 2022 | 177 | 2.940 |
Why?
|
Biomarkers | 41 | 2023 | 704 | 2.940 |
Why?
|
Epigenesis, Genetic | 18 | 2022 | 75 | 2.870 |
Why?
|
Synapses | 10 | 2021 | 49 | 2.860 |
Why?
|
Disability Evaluation | 23 | 2020 | 327 | 2.860 |
Why?
|
Membrane Transport Proteins | 11 | 2022 | 51 | 2.830 |
Why?
|
Mobility Limitation | 14 | 2021 | 97 | 2.830 |
Why?
|
Brain Diseases | 7 | 2021 | 83 | 2.820 |
Why?
|
Muscle Strength | 15 | 2021 | 129 | 2.800 |
Why?
|
Frail Elderly | 9 | 2021 | 51 | 2.800 |
Why?
|
DNA-Binding Proteins | 31 | 2023 | 263 | 2.750 |
Why?
|
Microglia | 20 | 2023 | 125 | 2.720 |
Why?
|
Loneliness | 10 | 2023 | 55 | 2.700 |
Why?
|
Genetic Variation | 24 | 2021 | 108 | 2.690 |
Why?
|
Olfaction Disorders | 11 | 2021 | 53 | 2.650 |
Why?
|
Genetic Loci | 21 | 2021 | 61 | 2.640 |
Why?
|
Lewy Body Disease | 18 | 2021 | 100 | 2.620 |
Why?
|
White Matter | 16 | 2022 | 150 | 2.580 |
Why?
|
Neuropathology | 15 | 2023 | 81 | 2.570 |
Why?
|
Genetic Association Studies | 24 | 2022 | 86 | 2.560 |
Why?
|
Personality | 9 | 2022 | 67 | 2.470 |
Why?
|
Incidence | 56 | 2021 | 759 | 2.420 |
Why?
|
Genome, Human | 9 | 2021 | 44 | 2.320 |
Why?
|
Sex Characteristics | 19 | 2022 | 135 | 2.290 |
Why?
|
Psychomotor Performance | 17 | 2021 | 220 | 2.260 |
Why?
|
Amyloid | 15 | 2022 | 54 | 2.230 |
Why?
|
Adaptor Proteins, Signal Transducing | 15 | 2021 | 78 | 2.220 |
Why?
|
Stress, Psychological | 12 | 2021 | 249 | 2.200 |
Why?
|
Frontal Lobe | 20 | 2022 | 85 | 2.190 |
Why?
|
Brain Mapping | 18 | 2022 | 199 | 2.190 |
Why?
|
Gene Expression | 16 | 2023 | 231 | 2.160 |
Why?
|
Chicago | 44 | 2021 | 867 | 2.150 |
Why?
|
Risk Assessment | 26 | 2022 | 683 | 2.130 |
Why?
|
Alleles | 34 | 2023 | 216 | 2.130 |
Why?
|
Arteriolosclerosis | 13 | 2023 | 74 | 2.090 |
Why?
|
Gray Matter | 7 | 2021 | 56 | 2.070 |
Why?
|
Social Behavior | 11 | 2021 | 99 | 2.070 |
Why?
|
Membrane Glycoproteins | 12 | 2021 | 102 | 2.010 |
Why?
|
Diabetes Mellitus, Type 2 | 10 | 2020 | 201 | 2.000 |
Why?
|
Proteome | 12 | 2023 | 40 | 1.990 |
Why?
|
Sex Factors | 37 | 2021 | 497 | 1.980 |
Why?
|
Multifactorial Inheritance | 13 | 2021 | 24 | 1.960 |
Why?
|
Comorbidity | 34 | 2021 | 504 | 1.920 |
Why?
|
Linear Models | 33 | 2023 | 258 | 1.920 |
Why?
|
Cross-Sectional Studies | 50 | 2023 | 970 | 1.880 |
Why?
|
Mental Recall | 13 | 2020 | 74 | 1.830 |
Why?
|
Receptors, Immunologic | 9 | 2021 | 34 | 1.810 |
Why?
|
Mortality | 10 | 2021 | 86 | 1.780 |
Why?
|
Gait | 17 | 2023 | 406 | 1.780 |
Why?
|
Brain Infarction | 13 | 2021 | 74 | 1.740 |
Why?
|
Risk | 32 | 2020 | 216 | 1.720 |
Why?
|
Motor Disorders | 4 | 2023 | 23 | 1.710 |
Why?
|
Temporal Lobe | 22 | 2021 | 109 | 1.700 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 4 | 2019 | 27 | 1.650 |
Why?
|
Phenotype | 31 | 2023 | 362 | 1.620 |
Why?
|
Neuroimaging | 13 | 2023 | 138 | 1.610 |
Why?
|
Time Factors | 36 | 2021 | 1641 | 1.590 |
Why?
|
Gait Disorders, Neurologic | 12 | 2018 | 144 | 1.590 |
Why?
|
Longevity | 10 | 2022 | 32 | 1.570 |
Why?
|
Movement Disorders | 8 | 2021 | 148 | 1.560 |
Why?
|
Walking Speed | 3 | 2021 | 41 | 1.560 |
Why?
|
Intracranial Arteriosclerosis | 12 | 2022 | 52 | 1.560 |
Why?
|
Frontotemporal Lobar Degeneration | 6 | 2022 | 28 | 1.560 |
Why?
|
Peptides | 7 | 2021 | 98 | 1.540 |
Why?
|
Quantitative Trait Loci | 20 | 2021 | 57 | 1.530 |
Why?
|
Hand Strength | 7 | 2023 | 60 | 1.520 |
Why?
|
Psychiatric Status Rating Scales | 24 | 2017 | 351 | 1.520 |
Why?
|
Frailty | 6 | 2023 | 39 | 1.500 |
Why?
|
Neural Pathways | 6 | 2014 | 82 | 1.500 |
Why?
|
Polymorphism, Genetic | 6 | 2017 | 74 | 1.480 |
Why?
|
Nerve Degeneration | 12 | 2021 | 55 | 1.480 |
Why?
|
Diet, Mediterranean | 10 | 2023 | 64 | 1.470 |
Why?
|
Animals | 68 | 2023 | 4638 | 1.470 |
Why?
|
Nuclear Proteins | 9 | 2021 | 86 | 1.460 |
Why?
|
Regression Analysis | 24 | 2021 | 298 | 1.460 |
Why?
|
Body Mass Index | 15 | 2023 | 425 | 1.450 |
Why?
|
Atherosclerosis | 5 | 2023 | 75 | 1.440 |
Why?
|
Choice Behavior | 4 | 2019 | 56 | 1.420 |
Why?
|
Substantia Nigra | 7 | 2021 | 149 | 1.400 |
Why?
|
Spinal Cord | 5 | 2022 | 106 | 1.390 |
Why?
|
Interpersonal Relations | 6 | 2014 | 105 | 1.380 |
Why?
|
Financial Management | 5 | 2020 | 25 | 1.380 |
Why?
|
Gene Expression Profiling | 18 | 2023 | 159 | 1.370 |
Why?
|
Life Style | 9 | 2021 | 212 | 1.350 |
Why?
|
Tumor Suppressor Proteins | 7 | 2021 | 33 | 1.340 |
Why?
|
Stroke | 10 | 2023 | 294 | 1.330 |
Why?
|
Severity of Illness Index | 36 | 2021 | 1126 | 1.330 |
Why?
|
Sleep | 13 | 2022 | 318 | 1.320 |
Why?
|
Quality of Life | 6 | 2015 | 677 | 1.320 |
Why?
|
Delay Discounting | 4 | 2023 | 26 | 1.300 |
Why?
|
Gene Expression Regulation | 23 | 2021 | 282 | 1.280 |
Why?
|
RNA, Messenger | 15 | 2022 | 324 | 1.270 |
Why?
|
Risk-Taking | 5 | 2019 | 32 | 1.250 |
Why?
|
Neocortex | 8 | 2019 | 34 | 1.230 |
Why?
|
Motor Skills | 7 | 2021 | 62 | 1.230 |
Why?
|
Fraud | 4 | 2022 | 23 | 1.220 |
Why?
|
Music | 2 | 2021 | 19 | 1.210 |
Why?
|
Cause of Death | 4 | 2021 | 64 | 1.200 |
Why?
|
Models, Statistical | 10 | 2020 | 132 | 1.190 |
Why?
|
Death | 5 | 2021 | 48 | 1.190 |
Why?
|
Muscle Weakness | 5 | 2021 | 34 | 1.190 |
Why?
|
Mental Health | 5 | 2016 | 105 | 1.180 |
Why?
|
Blood Pressure | 10 | 2022 | 252 | 1.180 |
Why?
|
Diabetes Mellitus | 10 | 2023 | 140 | 1.170 |
Why?
|
Epigenomics | 7 | 2021 | 12 | 1.140 |
Why?
|
Haplotypes | 10 | 2021 | 58 | 1.140 |
Why?
|
Circadian Rhythm | 9 | 2023 | 283 | 1.140 |
Why?
|
National Institute on Aging (U.S.) | 7 | 2022 | 18 | 1.140 |
Why?
|
Gene Regulatory Networks | 8 | 2020 | 34 | 1.130 |
Why?
|
Image Processing, Computer-Assisted | 15 | 2023 | 221 | 1.130 |
Why?
|
Cytomegalovirus Infections | 4 | 2015 | 82 | 1.130 |
Why?
|
Movement | 4 | 2020 | 146 | 1.120 |
Why?
|
Cardiovascular Diseases | 8 | 2023 | 411 | 1.110 |
Why?
|
Sarcopenia | 3 | 2021 | 26 | 1.100 |
Why?
|
Entorhinal Cortex | 15 | 2021 | 42 | 1.090 |
Why?
|
SNARE Proteins | 4 | 2021 | 14 | 1.070 |
Why?
|
Goals | 4 | 2017 | 43 | 1.070 |
Why?
|
Hemoglobins | 3 | 2012 | 83 | 1.060 |
Why?
|
Family | 4 | 2021 | 93 | 1.060 |
Why?
|
Literacy | 3 | 2021 | 15 | 1.050 |
Why?
|
Brain-Derived Neurotrophic Factor | 6 | 2021 | 40 | 1.050 |
Why?
|
Risk Reduction Behavior | 3 | 2015 | 55 | 1.050 |
Why?
|
Anxiety | 4 | 2013 | 157 | 1.030 |
Why?
|
Locus Coeruleus | 4 | 2021 | 23 | 1.020 |
Why?
|
Mice | 40 | 2023 | 1628 | 1.020 |
Why?
|
Anxiety Disorders | 5 | 2016 | 169 | 1.010 |
Why?
|
Diet | 11 | 2022 | 172 | 1.010 |
Why?
|
Wearable Electronic Devices | 3 | 2020 | 40 | 1.000 |
Why?
|
Brain Chemistry | 8 | 2021 | 46 | 1.000 |
Why?
|
Peptide Fragments | 16 | 2022 | 97 | 1.000 |
Why?
|
Sleep Deprivation | 6 | 2022 | 64 | 0.990 |
Why?
|
Proteins | 4 | 2020 | 71 | 0.990 |
Why?
|
Amyloidosis | 8 | 2022 | 27 | 0.990 |
Why?
|
Logistic Models | 25 | 2020 | 410 | 0.990 |
Why?
|
Mice, Transgenic | 29 | 2022 | 256 | 0.980 |
Why?
|
Adult | 58 | 2023 | 8741 | 0.980 |
Why?
|
Case-Control Studies | 31 | 2021 | 641 | 0.970 |
Why?
|
Hypertension | 11 | 2022 | 272 | 0.970 |
Why?
|
Histones | 3 | 2019 | 28 | 0.960 |
Why?
|
Brazil | 5 | 2021 | 37 | 0.960 |
Why?
|
Economics | 4 | 2019 | 18 | 0.960 |
Why?
|
Psychometrics | 22 | 2017 | 264 | 0.950 |
Why?
|
Physical Fitness | 4 | 2016 | 59 | 0.950 |
Why?
|
Self Report | 11 | 2022 | 221 | 0.950 |
Why?
|
Depressive Disorder, Major | 5 | 2017 | 106 | 0.950 |
Why?
|
alpha-Synuclein | 11 | 2021 | 139 | 0.950 |
Why?
|
Mental Status Schedule | 17 | 2018 | 114 | 0.950 |
Why?
|
Odorants | 6 | 2021 | 23 | 0.940 |
Why?
|
CpG Islands | 10 | 2021 | 34 | 0.940 |
Why?
|
Statistics as Topic | 20 | 2017 | 114 | 0.930 |
Why?
|
Homozygote | 4 | 2020 | 22 | 0.920 |
Why?
|
Atrophy | 17 | 2021 | 106 | 0.920 |
Why?
|
Sequence Analysis, RNA | 13 | 2023 | 43 | 0.910 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2020 | 6 | 0.900 |
Why?
|
Depressive Disorder | 9 | 2019 | 191 | 0.890 |
Why?
|
Diffusion Tensor Imaging | 8 | 2023 | 84 | 0.890 |
Why?
|
LDL-Receptor Related Proteins | 6 | 2022 | 14 | 0.890 |
Why?
|
Antibodies, Antiphospholipid | 3 | 2019 | 26 | 0.890 |
Why?
|
Adaptation, Psychological | 3 | 2020 | 143 | 0.890 |
Why?
|
MicroRNAs | 6 | 2022 | 44 | 0.880 |
Why?
|
Algorithms | 11 | 2021 | 400 | 0.880 |
Why?
|
Research Design | 7 | 2021 | 214 | 0.880 |
Why?
|
HSP27 Heat-Shock Proteins | 3 | 2019 | 19 | 0.880 |
Why?
|
Inflammation | 9 | 2022 | 347 | 0.870 |
Why?
|
Cerebrum | 1 | 2023 | 10 | 0.860 |
Why?
|
Social Environment | 4 | 2021 | 81 | 0.860 |
Why?
|
Dementia, Vascular | 9 | 2018 | 44 | 0.850 |
Why?
|
Prevalence | 22 | 2019 | 494 | 0.850 |
Why?
|
Learning | 4 | 2018 | 80 | 0.850 |
Why?
|
Actigraphy | 17 | 2022 | 98 | 0.850 |
Why?
|
Nerve Net | 4 | 2019 | 54 | 0.830 |
Why?
|
Financing, Personal | 5 | 2020 | 19 | 0.830 |
Why?
|
Clergy | 14 | 2013 | 90 | 0.830 |
Why?
|
Causality | 11 | 2021 | 52 | 0.820 |
Why?
|
Attention | 5 | 2009 | 145 | 0.820 |
Why?
|
Apolipoprotein E3 | 6 | 2022 | 17 | 0.820 |
Why?
|
Neoplasms | 4 | 2018 | 257 | 0.810 |
Why?
|
Memory, Short-Term | 10 | 2021 | 103 | 0.810 |
Why?
|
Visual Perception | 7 | 2017 | 50 | 0.800 |
Why?
|
Vascular Diseases | 5 | 2021 | 53 | 0.800 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 64 | 0.800 |
Why?
|
Muscle Rigidity | 7 | 2014 | 26 | 0.790 |
Why?
|
Mental Status and Dementia Tests | 7 | 2021 | 81 | 0.790 |
Why?
|
Health Status | 7 | 2019 | 230 | 0.790 |
Why?
|
Memory and Learning Tests | 2 | 2020 | 7 | 0.790 |
Why?
|
Postural Balance | 6 | 2018 | 122 | 0.790 |
Why?
|
Cerebral Arterial Diseases | 1 | 2021 | 8 | 0.780 |
Why?
|
Receptors, IgG | 2 | 2021 | 19 | 0.780 |
Why?
|
Models, Psychological | 4 | 2015 | 67 | 0.770 |
Why?
|
Sclerosis | 10 | 2022 | 68 | 0.760 |
Why?
|
Microvessels | 2 | 2019 | 16 | 0.760 |
Why?
|
Muscle, Skeletal | 6 | 2021 | 355 | 0.760 |
Why?
|
Social Discrimination | 1 | 2021 | 6 | 0.750 |
Why?
|
Motor Neurons | 2 | 2018 | 21 | 0.750 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2021 | 119 | 0.750 |
Why?
|
Carrier Proteins | 4 | 2021 | 99 | 0.750 |
Why?
|
Emotions | 2 | 2012 | 90 | 0.750 |
Why?
|
Serial Learning | 1 | 2020 | 8 | 0.740 |
Why?
|
Astrocytes | 8 | 2022 | 122 | 0.740 |
Why?
|
Galectin 3 | 1 | 2020 | 3 | 0.740 |
Why?
|
Galectins | 1 | 2020 | 6 | 0.740 |
Why?
|
Galectin 1 | 1 | 2020 | 4 | 0.740 |
Why?
|
RNA | 8 | 2023 | 40 | 0.740 |
Why?
|
Information Literacy | 3 | 2019 | 9 | 0.740 |
Why?
|
Immunohistochemistry | 23 | 2021 | 411 | 0.730 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 12 | 0.730 |
Why?
|
Crime Victims | 2 | 2022 | 25 | 0.720 |
Why?
|
Parietal Lobe | 6 | 2021 | 22 | 0.720 |
Why?
|
Transcription Factors | 9 | 2021 | 166 | 0.710 |
Why?
|
Genomics | 3 | 2021 | 43 | 0.710 |
Why?
|
Leg | 4 | 2008 | 49 | 0.710 |
Why?
|
Agnosia | 2 | 2012 | 10 | 0.710 |
Why?
|
Intelligence | 2 | 2020 | 25 | 0.710 |
Why?
|
Musculoskeletal Diseases | 2 | 2010 | 41 | 0.700 |
Why?
|
ATP-Binding Cassette Transporters | 5 | 2016 | 17 | 0.700 |
Why?
|
Delivery of Health Care | 7 | 2023 | 156 | 0.700 |
Why?
|
HIV Infections | 4 | 2020 | 997 | 0.690 |
Why?
|
Child Development | 1 | 2020 | 71 | 0.690 |
Why?
|
Drug Discovery | 2 | 2017 | 21 | 0.690 |
Why?
|
Awareness | 2 | 2019 | 38 | 0.690 |
Why?
|
Language | 5 | 2018 | 78 | 0.690 |
Why?
|
Adenylate Kinase | 1 | 2019 | 7 | 0.680 |
Why?
|
Disease Models, Animal | 20 | 2022 | 744 | 0.680 |
Why?
|
Child Abuse | 2 | 2012 | 36 | 0.680 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 14 | 0.680 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2009 | 107 | 0.680 |
Why?
|
Neurologic Examination | 13 | 2020 | 154 | 0.670 |
Why?
|
Metabolomics | 6 | 2021 | 23 | 0.670 |
Why?
|
Physicians | 2 | 2020 | 116 | 0.660 |
Why?
|
Caspase 6 | 7 | 2016 | 7 | 0.660 |
Why?
|
Bayes Theorem | 7 | 2021 | 39 | 0.660 |
Why?
|
Reward | 3 | 2019 | 34 | 0.650 |
Why?
|
Socioeconomic Factors | 12 | 2020 | 329 | 0.650 |
Why?
|
Neuroticism | 9 | 2022 | 34 | 0.650 |
Why?
|
Age of Onset | 14 | 2022 | 108 | 0.640 |
Why?
|
Brain Injuries, Traumatic | 4 | 2022 | 26 | 0.640 |
Why?
|
Models, Neurological | 3 | 2016 | 32 | 0.640 |
Why?
|
Reading | 9 | 2021 | 40 | 0.630 |
Why?
|
Endophenotypes | 5 | 2015 | 12 | 0.630 |
Why?
|
Epidemiologic Studies | 5 | 2012 | 23 | 0.630 |
Why?
|
Odds Ratio | 17 | 2018 | 286 | 0.630 |
Why?
|
Kidney | 2 | 2010 | 176 | 0.630 |
Why?
|
Pain | 3 | 2023 | 397 | 0.620 |
Why?
|
Comprehension | 3 | 2016 | 28 | 0.620 |
Why?
|
Qa-SNARE Proteins | 2 | 2021 | 7 | 0.620 |
Why?
|
Lung | 2 | 2009 | 158 | 0.620 |
Why?
|
Adaptor Proteins, Vesicular Transport | 4 | 2021 | 42 | 0.610 |
Why?
|
Interviews as Topic | 4 | 2021 | 130 | 0.610 |
Why?
|
Ankyrins | 2 | 2014 | 4 | 0.610 |
Why?
|
Psychological Tests | 7 | 2015 | 52 | 0.610 |
Why?
|
Perception | 5 | 2021 | 83 | 0.600 |
Why?
|
Prognosis | 13 | 2020 | 874 | 0.600 |
Why?
|
Neuropeptides | 4 | 2023 | 30 | 0.600 |
Why?
|
Tauopathies | 5 | 2023 | 18 | 0.600 |
Why?
|
Diagnosis, Differential | 8 | 2011 | 399 | 0.590 |
Why?
|
Dietary Approaches To Stop Hypertension | 3 | 2023 | 21 | 0.590 |
Why?
|
Drosophila melanogaster | 5 | 2019 | 18 | 0.570 |
Why?
|
Brain Stem | 2 | 2016 | 25 | 0.570 |
Why?
|
Personal Satisfaction | 2 | 2016 | 48 | 0.560 |
Why?
|
Executive Function | 8 | 2023 | 124 | 0.560 |
Why?
|
Predictive Value of Tests | 15 | 2016 | 532 | 0.560 |
Why?
|
Nucleus Accumbens | 1 | 2016 | 25 | 0.560 |
Why?
|
Microfilament Proteins | 4 | 2019 | 22 | 0.550 |
Why?
|
Hospitalization | 5 | 2019 | 319 | 0.550 |
Why?
|
Metabolome | 4 | 2020 | 16 | 0.550 |
Why?
|
Reaction Time | 10 | 2021 | 124 | 0.550 |
Why?
|
Positron-Emission Tomography | 9 | 2023 | 91 | 0.550 |
Why?
|
Receptors, Complement 3b | 6 | 2016 | 15 | 0.540 |
Why?
|
Income | 7 | 2023 | 77 | 0.540 |
Why?
|
Amyloid beta-Protein Precursor | 8 | 2022 | 22 | 0.540 |
Why?
|
Life | 2 | 2006 | 7 | 0.540 |
Why?
|
Apolipoprotein E2 | 5 | 2023 | 12 | 0.540 |
Why?
|
Cerebellum | 5 | 2016 | 53 | 0.530 |
Why?
|
Child | 14 | 2020 | 1377 | 0.530 |
Why?
|
Olfactory Bulb | 3 | 2023 | 17 | 0.530 |
Why?
|
Oxygen Consumption | 1 | 2016 | 51 | 0.530 |
Why?
|
Intention | 3 | 2010 | 26 | 0.530 |
Why?
|
Population Surveillance | 2 | 2017 | 118 | 0.530 |
Why?
|
Tissue Donors | 4 | 2020 | 73 | 0.520 |
Why?
|
Chronic Disease | 7 | 2017 | 508 | 0.520 |
Why?
|
Signal Transduction | 14 | 2021 | 491 | 0.520 |
Why?
|
Body Composition | 3 | 2019 | 57 | 0.510 |
Why?
|
Gene Frequency | 14 | 2018 | 72 | 0.510 |
Why?
|
Diabetes Complications | 8 | 2021 | 64 | 0.510 |
Why?
|
Survival Rate | 3 | 2012 | 376 | 0.510 |
Why?
|
Reference Values | 9 | 2020 | 230 | 0.510 |
Why?
|
Association | 2 | 2012 | 8 | 0.500 |
Why?
|
Trust | 2 | 2019 | 16 | 0.500 |
Why?
|
Mutation | 9 | 2022 | 397 | 0.500 |
Why?
|
Antiporters | 1 | 2015 | 5 | 0.500 |
Why?
|
HLA-DRB5 Chains | 1 | 2015 | 5 | 0.500 |
Why?
|
Data Interpretation, Statistical | 13 | 2022 | 97 | 0.500 |
Why?
|
Illinois | 8 | 2020 | 241 | 0.500 |
Why?
|
Sleep Wake Disorders | 5 | 2019 | 148 | 0.500 |
Why?
|
Exercise Test | 1 | 2016 | 124 | 0.490 |
Why?
|
Reproducibility of Results | 18 | 2022 | 802 | 0.490 |
Why?
|
Prodromal Symptoms | 4 | 2020 | 19 | 0.490 |
Why?
|
Postmortem Changes | 9 | 2019 | 34 | 0.490 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 223 | 0.490 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 7 | 2017 | 15 | 0.490 |
Why?
|
Seafood | 4 | 2018 | 9 | 0.490 |
Why?
|
Social Isolation | 4 | 2023 | 23 | 0.480 |
Why?
|
Neurotic Disorders | 4 | 2011 | 19 | 0.480 |
Why?
|
Heterozygote | 8 | 2021 | 103 | 0.480 |
Why?
|
Multilingualism | 1 | 2014 | 11 | 0.480 |
Why?
|
Harm Reduction | 1 | 2014 | 5 | 0.480 |
Why?
|
Respiratory Muscles | 3 | 2008 | 18 | 0.470 |
Why?
|
Gyrus Cinguli | 1 | 2014 | 22 | 0.470 |
Why?
|
CLOCK Proteins | 2 | 2017 | 26 | 0.470 |
Why?
|
Poverty | 1 | 2015 | 97 | 0.470 |
Why?
|
Disease Susceptibility | 7 | 2019 | 78 | 0.470 |
Why?
|
Health Behavior | 5 | 2021 | 159 | 0.470 |
Why?
|
Smell | 3 | 2021 | 18 | 0.470 |
Why?
|
Locomotion | 1 | 2014 | 24 | 0.460 |
Why?
|
Verbal Learning | 5 | 2014 | 43 | 0.450 |
Why?
|
Acculturation | 3 | 2023 | 35 | 0.450 |
Why?
|
Mesencephalon | 1 | 2013 | 47 | 0.450 |
Why?
|
Bile Acids and Salts | 4 | 2021 | 11 | 0.450 |
Why?
|
Mental Disorders | 5 | 2021 | 142 | 0.450 |
Why?
|
Organ Size | 10 | 2019 | 107 | 0.450 |
Why?
|
Social Support | 4 | 2020 | 186 | 0.450 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2013 | 26 | 0.440 |
Why?
|
Dyssomnias | 1 | 2013 | 8 | 0.440 |
Why?
|
Survival Analysis | 11 | 2019 | 310 | 0.440 |
Why?
|
Psychomotor Disorders | 1 | 2013 | 10 | 0.440 |
Why?
|
Automobile Driving | 2 | 2012 | 12 | 0.430 |
Why?
|
Immunotherapy | 2 | 2021 | 66 | 0.430 |
Why?
|
Consensus | 1 | 2013 | 109 | 0.430 |
Why?
|
Receptors, Estrogen | 2 | 2023 | 68 | 0.430 |
Why?
|
Vision Disorders | 1 | 2012 | 24 | 0.430 |
Why?
|
Self Stimulation | 2 | 2003 | 12 | 0.430 |
Why?
|
RNA Splicing | 4 | 2019 | 11 | 0.430 |
Why?
|
Insulin | 5 | 2021 | 92 | 0.420 |
Why?
|
Musculoskeletal Pain | 1 | 2012 | 20 | 0.420 |
Why?
|
Cholesterol Ester Transfer Proteins | 2 | 2011 | 5 | 0.420 |
Why?
|
Anisotropy | 6 | 2023 | 60 | 0.420 |
Why?
|
Parkinson Disease, Secondary | 3 | 2005 | 29 | 0.420 |
Why?
|
Databases, Factual | 3 | 2020 | 331 | 0.420 |
Why?
|
Synaptosomal-Associated Protein 25 | 1 | 2012 | 3 | 0.420 |
Why?
|
Data Collection | 3 | 2010 | 108 | 0.420 |
Why?
|
Induced Pluripotent Stem Cells | 4 | 2021 | 16 | 0.410 |
Why?
|
Terminally Ill | 1 | 2012 | 5 | 0.410 |
Why?
|
Cytoskeletal Proteins | 4 | 2019 | 25 | 0.410 |
Why?
|
Accelerometry | 4 | 2020 | 87 | 0.410 |
Why?
|
Social Class | 5 | 2022 | 65 | 0.410 |
Why?
|
Limbic Encephalitis | 2 | 2023 | 11 | 0.410 |
Why?
|
Surveys and Questionnaires | 12 | 2021 | 1187 | 0.400 |
Why?
|
DNA Copy Number Variations | 2 | 2021 | 10 | 0.400 |
Why?
|
Synaptotagmins | 2 | 2021 | 5 | 0.400 |
Why?
|
Social Adjustment | 2 | 2009 | 29 | 0.400 |
Why?
|
C-Reactive Protein | 1 | 2012 | 125 | 0.400 |
Why?
|
Confidence Intervals | 9 | 2012 | 96 | 0.400 |
Why?
|
Periodicals as Topic | 1 | 2012 | 41 | 0.390 |
Why?
|
Fatigue | 2 | 2009 | 63 | 0.390 |
Why?
|
Young Adult | 15 | 2020 | 1966 | 0.390 |
Why?
|
Amygdala | 3 | 2021 | 50 | 0.390 |
Why?
|
September 11 Terrorist Attacks | 2 | 2021 | 11 | 0.390 |
Why?
|
Medicare | 5 | 2024 | 123 | 0.390 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2021 | 190 | 0.390 |
Why?
|
Self-Assessment | 3 | 2021 | 29 | 0.390 |
Why?
|
Community Health Services | 2 | 2009 | 31 | 0.390 |
Why?
|
Housing for the Elderly | 2 | 2010 | 7 | 0.390 |
Why?
|
Chronic Pain | 1 | 2012 | 112 | 0.380 |
Why?
|
Schizophrenia | 5 | 2018 | 70 | 0.380 |
Why?
|
Genetic Testing | 7 | 2019 | 62 | 0.380 |
Why?
|
Urban Population | 11 | 2011 | 143 | 0.380 |
Why?
|
Cerebral Small Vessel Diseases | 2 | 2021 | 12 | 0.380 |
Why?
|
Diffusion Magnetic Resonance Imaging | 4 | 2022 | 96 | 0.380 |
Why?
|
Sex Distribution | 6 | 2014 | 86 | 0.380 |
Why?
|
Social Participation | 1 | 2011 | 11 | 0.380 |
Why?
|
Population Groups | 2 | 2021 | 5 | 0.370 |
Why?
|
Psychology | 3 | 2021 | 21 | 0.370 |
Why?
|
Drosophila Proteins | 3 | 2019 | 11 | 0.370 |
Why?
|
Environmental Health | 1 | 2010 | 8 | 0.370 |
Why?
|
Statistics, Nonparametric | 7 | 2015 | 137 | 0.370 |
Why?
|
RNA Splicing Factors | 2 | 2020 | 5 | 0.370 |
Why?
|
Motor Skills Disorders | 1 | 2010 | 18 | 0.370 |
Why?
|
Hypokinesia | 5 | 2014 | 27 | 0.370 |
Why?
|
Knowledge | 1 | 2010 | 19 | 0.370 |
Why?
|
Mitochondria | 5 | 2021 | 84 | 0.360 |
Why?
|
Fatty Acids | 5 | 2022 | 39 | 0.360 |
Why?
|
Walking | 6 | 2023 | 255 | 0.360 |
Why?
|
Pericytes | 2 | 2020 | 5 | 0.360 |
Why?
|
Molecular Chaperones | 3 | 2020 | 13 | 0.360 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 2021 | 8 | 0.360 |
Why?
|
Models, Biological | 7 | 2019 | 347 | 0.360 |
Why?
|
Phobic Disorders | 1 | 2010 | 65 | 0.360 |
Why?
|
Affect | 2 | 2016 | 65 | 0.360 |
Why?
|
Potassium | 1 | 2010 | 68 | 0.350 |
Why?
|
Reactive Oxygen Species | 6 | 2022 | 130 | 0.350 |
Why?
|
Computational Biology | 6 | 2020 | 24 | 0.350 |
Why?
|
Synapsins | 2 | 2021 | 6 | 0.350 |
Why?
|
Blood Glucose | 2 | 2022 | 112 | 0.350 |
Why?
|
Oxidative Stress | 7 | 2022 | 131 | 0.350 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2017 | 81 | 0.350 |
Why?
|
Community Health Planning | 3 | 2018 | 21 | 0.340 |
Why?
|
Protein Interaction Maps | 4 | 2018 | 17 | 0.340 |
Why?
|
Analysis of Variance | 9 | 2021 | 325 | 0.340 |
Why?
|
Proteostasis | 2 | 2019 | 3 | 0.340 |
Why?
|
Somatosensory Disorders | 1 | 2009 | 10 | 0.340 |
Why?
|
Sensory Thresholds | 1 | 2009 | 24 | 0.340 |
Why?
|
Phosphorylation | 11 | 2021 | 159 | 0.340 |
Why?
|
Cell Count | 8 | 2015 | 97 | 0.330 |
Why?
|
Neoplasm Proteins | 3 | 2019 | 53 | 0.330 |
Why?
|
Adolescent | 14 | 2020 | 2332 | 0.330 |
Why?
|
Vibration | 1 | 2009 | 26 | 0.330 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2020 | 56 | 0.330 |
Why?
|
Leisure Activities | 2 | 2006 | 12 | 0.330 |
Why?
|
Catholicism | 6 | 2013 | 21 | 0.330 |
Why?
|
Energy Metabolism | 4 | 2020 | 53 | 0.320 |
Why?
|
Neurodevelopmental Disorders | 2 | 2019 | 20 | 0.320 |
Why?
|
Sensitivity and Specificity | 6 | 2021 | 558 | 0.320 |
Why?
|
Presenilin-1 | 4 | 2021 | 7 | 0.320 |
Why?
|
Repressor Proteins | 3 | 2019 | 30 | 0.320 |
Why?
|
Transcription, Genetic | 6 | 2020 | 108 | 0.320 |
Why?
|
Accidental Falls | 1 | 2010 | 117 | 0.310 |
Why?
|
Protein Processing, Post-Translational | 5 | 2021 | 36 | 0.310 |
Why?
|
Fatty Acids, Omega-3 | 4 | 2016 | 15 | 0.310 |
Why?
|
Tremor | 7 | 2014 | 143 | 0.310 |
Why?
|
Estrogen Receptor beta | 1 | 2008 | 4 | 0.310 |
Why?
|
Neuroimmunomodulation | 1 | 2008 | 9 | 0.310 |
Why?
|
Estrogen Receptor alpha | 1 | 2008 | 15 | 0.310 |
Why?
|
Rest | 4 | 2023 | 33 | 0.310 |
Why?
|
Clusterin | 4 | 2012 | 4 | 0.310 |
Why?
|
Body Size | 2 | 2019 | 11 | 0.300 |
Why?
|
Seasons | 2 | 2018 | 31 | 0.300 |
Why?
|
Urinary Incontinence | 3 | 2017 | 24 | 0.300 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 50 | 0.300 |
Why?
|
Phospholipases A2, Cytosolic | 3 | 2022 | 6 | 0.300 |
Why?
|
Age Distribution | 7 | 2014 | 95 | 0.300 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2009 | 97 | 0.300 |
Why?
|
Metabolic Networks and Pathways | 4 | 2021 | 14 | 0.300 |
Why?
|
Isometric Contraction | 1 | 2007 | 15 | 0.300 |
Why?
|
Diagnosis | 5 | 2019 | 23 | 0.300 |
Why?
|
DNA, Mitochondrial | 3 | 2021 | 9 | 0.300 |
Why?
|
Smoking | 6 | 2020 | 194 | 0.290 |
Why?
|
Nerve Growth Factor | 4 | 2020 | 33 | 0.290 |
Why?
|
Chromatography, Liquid | 3 | 2022 | 25 | 0.290 |
Why?
|
GPI-Linked Proteins | 3 | 2023 | 26 | 0.290 |
Why?
|
Hormone Replacement Therapy | 2 | 2020 | 30 | 0.290 |
Why?
|
Lower Extremity | 1 | 2007 | 38 | 0.290 |
Why?
|
Vascular Endothelial Growth Factor A | 4 | 2023 | 69 | 0.290 |
Why?
|
Epoxide Hydrolases | 3 | 2022 | 10 | 0.290 |
Why?
|
Personal Space | 1 | 2007 | 6 | 0.290 |
Why?
|
Space Perception | 3 | 2019 | 28 | 0.290 |
Why?
|
Linkage Disequilibrium | 9 | 2021 | 39 | 0.290 |
Why?
|
Personality Disorders | 2 | 2006 | 19 | 0.290 |
Why?
|
Insulin Resistance | 2 | 2021 | 61 | 0.280 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 79 | 0.280 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2021 | 17 | 0.280 |
Why?
|
Dyskinesias | 1 | 2006 | 35 | 0.280 |
Why?
|
Factor Analysis, Statistical | 7 | 2015 | 78 | 0.280 |
Why?
|
Infarction | 4 | 2023 | 25 | 0.270 |
Why?
|
Mitochondrial Proteins | 3 | 2021 | 21 | 0.270 |
Why?
|
Chromosome Mapping | 4 | 2019 | 38 | 0.270 |
Why?
|
Ischemic Attack, Transient | 1 | 2006 | 20 | 0.270 |
Why?
|
Decision Support Techniques | 1 | 2006 | 51 | 0.270 |
Why?
|
Television | 1 | 2006 | 6 | 0.270 |
Why?
|
Down-Regulation | 6 | 2015 | 112 | 0.270 |
Why?
|
Probability | 6 | 2021 | 93 | 0.270 |
Why?
|
Up-Regulation | 5 | 2021 | 173 | 0.270 |
Why?
|
Drosophila | 2 | 2019 | 7 | 0.270 |
Why?
|
Nerve Growth Factors | 2 | 2023 | 49 | 0.270 |
Why?
|
ROC Curve | 4 | 2022 | 140 | 0.270 |
Why?
|
Heme Oxygenase-1 | 3 | 2014 | 7 | 0.270 |
Why?
|
Exercise Therapy | 1 | 2007 | 112 | 0.260 |
Why?
|
Extracellular Matrix Proteins | 4 | 2019 | 131 | 0.260 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 7 | 0.260 |
Why?
|
Antioxidants | 3 | 2020 | 61 | 0.260 |
Why?
|
Alternative Splicing | 4 | 2018 | 25 | 0.260 |
Why?
|
Leukocytes, Mononuclear | 3 | 2022 | 98 | 0.260 |
Why?
|
Functional Laterality | 3 | 2008 | 94 | 0.260 |
Why?
|
Cachexia | 1 | 2005 | 11 | 0.260 |
Why?
|
Monomeric Clathrin Assembly Proteins | 5 | 2012 | 7 | 0.260 |
Why?
|
Health Status Disparities | 2 | 2017 | 70 | 0.260 |
Why?
|
Demography | 6 | 2018 | 78 | 0.260 |
Why?
|
Respiratory Function Tests | 2 | 2019 | 33 | 0.260 |
Why?
|
Infant | 4 | 2023 | 542 | 0.260 |
Why?
|
Psychotic Disorders | 4 | 2017 | 42 | 0.260 |
Why?
|
Amnesia | 2 | 2021 | 27 | 0.260 |
Why?
|
Renal Dialysis | 1 | 2006 | 110 | 0.260 |
Why?
|
Microtubule-Associated Proteins | 5 | 2021 | 21 | 0.250 |
Why?
|
Heart Diseases | 2 | 2016 | 75 | 0.250 |
Why?
|
ARNTL Transcription Factors | 2 | 2016 | 9 | 0.250 |
Why?
|
Blotting, Western | 11 | 2017 | 175 | 0.250 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 10 | 2019 | 132 | 0.250 |
Why?
|
Aspartic Acid Endopeptidases | 4 | 2021 | 9 | 0.250 |
Why?
|
Complement C4 | 2 | 2022 | 4 | 0.250 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2004 | 3 | 0.250 |
Why?
|
Receptors, Muscarinic | 1 | 2004 | 6 | 0.250 |
Why?
|
Synaptic Membranes | 1 | 2004 | 3 | 0.250 |
Why?
|
Cell Nucleus | 4 | 2020 | 80 | 0.250 |
Why?
|
Chromatin | 2 | 2016 | 14 | 0.240 |
Why?
|
Diabetic Neuropathies | 1 | 2004 | 14 | 0.240 |
Why?
|
Tandem Mass Spectrometry | 2 | 2022 | 27 | 0.240 |
Why?
|
Antihypertensive Agents | 4 | 2020 | 85 | 0.240 |
Why?
|
Personality Inventory | 4 | 2022 | 74 | 0.240 |
Why?
|
Amyloid Precursor Protein Secretases | 5 | 2022 | 17 | 0.240 |
Why?
|
Epistasis, Genetic | 3 | 2021 | 8 | 0.240 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 158 | 0.240 |
Why?
|
Genome | 2 | 2016 | 14 | 0.240 |
Why?
|
Retrospective Studies | 7 | 2021 | 3325 | 0.240 |
Why?
|
Cells, Cultured | 8 | 2021 | 682 | 0.240 |
Why?
|
Neprilysin | 3 | 2019 | 9 | 0.240 |
Why?
|
Family Health | 2 | 2017 | 35 | 0.230 |
Why?
|
Clinical Trials as Topic | 7 | 2014 | 337 | 0.230 |
Why?
|
Vesicular Transport Proteins | 2 | 2020 | 9 | 0.230 |
Why?
|
Multiple Sclerosis | 2 | 2022 | 87 | 0.230 |
Why?
|
Cerebral Arteries | 3 | 2016 | 31 | 0.230 |
Why?
|
Primary Prevention | 2 | 2019 | 39 | 0.230 |
Why?
|
Bone Diseases, Metabolic | 1 | 2023 | 19 | 0.230 |
Why?
|
Lipid Metabolism | 3 | 2019 | 31 | 0.230 |
Why?
|
Anthocyanins | 2 | 2022 | 7 | 0.230 |
Why?
|
Estrogen Replacement Therapy | 1 | 2023 | 21 | 0.230 |
Why?
|
Government | 1 | 2023 | 3 | 0.230 |
Why?
|
Choline O-Acetyltransferase | 5 | 2005 | 16 | 0.230 |
Why?
|
Synaptophysin | 2 | 2021 | 9 | 0.220 |
Why?
|
Benchmarking | 1 | 2023 | 42 | 0.220 |
Why?
|
Public Health | 2 | 2001 | 62 | 0.220 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2018 | 19 | 0.220 |
Why?
|
Protein Isoforms | 5 | 2020 | 52 | 0.220 |
Why?
|
Metformin | 1 | 2023 | 23 | 0.220 |
Why?
|
Resilience, Psychological | 1 | 2023 | 25 | 0.220 |
Why?
|
Anger | 1 | 2003 | 31 | 0.220 |
Why?
|
Range of Motion, Articular | 2 | 2019 | 707 | 0.220 |
Why?
|
Inclusion Bodies | 3 | 2014 | 14 | 0.220 |
Why?
|
Adaptor Protein Complex 1 | 1 | 2023 | 5 | 0.220 |
Why?
|
Adaptor Protein Complex beta Subunits | 1 | 2023 | 5 | 0.220 |
Why?
|
Gene-Environment Interaction | 4 | 2020 | 19 | 0.220 |
Why?
|
Calcium | 3 | 2022 | 498 | 0.220 |
Why?
|
Mice, Inbred C57BL | 8 | 2020 | 435 | 0.220 |
Why?
|
Aniline Compounds | 5 | 2017 | 41 | 0.220 |
Why?
|
Nociceptors | 1 | 2023 | 20 | 0.220 |
Why?
|
Heart Failure | 2 | 2021 | 207 | 0.220 |
Why?
|
Insulins | 1 | 2022 | 4 | 0.220 |
Why?
|
Acetylation | 2 | 2019 | 13 | 0.210 |
Why?
|
Period Circadian Proteins | 2 | 2013 | 23 | 0.210 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2002 | 9 | 0.210 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2023 | 14 | 0.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2017 | 38 | 0.210 |
Why?
|
Exonucleases | 1 | 2022 | 2 | 0.210 |
Why?
|
Glycopeptides | 1 | 2022 | 5 | 0.210 |
Why?
|
Group IV Phospholipases A2 | 1 | 2022 | 4 | 0.210 |
Why?
|
Retirement | 3 | 2011 | 11 | 0.210 |
Why?
|
Prenatal Care | 2 | 2020 | 8 | 0.210 |
Why?
|
Protein Kinases | 2 | 2021 | 15 | 0.210 |
Why?
|
Hallucinations | 4 | 2005 | 87 | 0.210 |
Why?
|
Posture | 3 | 2014 | 79 | 0.210 |
Why?
|
Neural Stem Cells | 2 | 2019 | 14 | 0.210 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2022 | 2 | 0.210 |
Why?
|
Forecasting | 4 | 2014 | 117 | 0.210 |
Why?
|
Glycation End Products, Advanced | 1 | 2022 | 7 | 0.210 |
Why?
|
Stem Cells | 1 | 2022 | 49 | 0.200 |
Why?
|
Radar | 1 | 2022 | 6 | 0.200 |
Why?
|
Caenorhabditis elegans Proteins | 2 | 2019 | 4 | 0.200 |
Why?
|
Child, Preschool | 5 | 2022 | 654 | 0.200 |
Why?
|
United Kingdom | 5 | 2021 | 51 | 0.200 |
Why?
|
ORAI2 Protein | 1 | 2021 | 1 | 0.200 |
Why?
|
RNA Editing | 1 | 2021 | 1 | 0.200 |
Why?
|
Chi-Square Distribution | 3 | 2018 | 147 | 0.200 |
Why?
|
Platelet Activation | 1 | 2021 | 4 | 0.200 |
Why?
|
Individuality | 3 | 2022 | 22 | 0.200 |
Why?
|
Genetic Diseases, Inborn | 1 | 2021 | 5 | 0.200 |
Why?
|
Vitamin A | 1 | 2021 | 6 | 0.200 |
Why?
|
Megakaryocytes | 1 | 2021 | 26 | 0.200 |
Why?
|
Verbal Behavior | 2 | 2016 | 20 | 0.200 |
Why?
|
Metacognition | 1 | 2021 | 3 | 0.200 |
Why?
|
Synaptosomes | 5 | 2022 | 8 | 0.200 |
Why?
|
Chromosomes, Human, X | 1 | 2021 | 8 | 0.200 |
Why?
|
Protein Prenylation | 1 | 2021 | 1 | 0.200 |
Why?
|
Farnesyltranstransferase | 1 | 2021 | 1 | 0.200 |
Why?
|
Judgment | 2 | 2012 | 9 | 0.200 |
Why?
|
Protein Biosynthesis | 2 | 2022 | 25 | 0.200 |
Why?
|
Device Approval | 1 | 2021 | 15 | 0.200 |
Why?
|
History, 19th Century | 1 | 2021 | 76 | 0.200 |
Why?
|
Elder Abuse | 1 | 2022 | 34 | 0.200 |
Why?
|
Amyotrophic Lateral Sclerosis | 2 | 2019 | 23 | 0.200 |
Why?
|
Netrins | 1 | 2021 | 2 | 0.200 |
Why?
|
Rats | 8 | 2021 | 876 | 0.190 |
Why?
|
Homeodomain Proteins | 2 | 2020 | 55 | 0.190 |
Why?
|
Anemia | 2 | 2014 | 99 | 0.190 |
Why?
|
Ion Mobility Spectrometry | 1 | 2021 | 1 | 0.190 |
Why?
|
History, 20th Century | 1 | 2021 | 91 | 0.190 |
Why?
|
Phospholipase D | 1 | 2021 | 5 | 0.190 |
Why?
|
beta-Lactamases | 1 | 2021 | 72 | 0.190 |
Why?
|
Vitamin E | 4 | 2020 | 27 | 0.190 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2021 | 20 | 0.190 |
Why?
|
Environmental Pollutants | 1 | 2021 | 3 | 0.190 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2021 | 6 | 0.190 |
Why?
|
Oxygen | 2 | 2011 | 86 | 0.190 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 38 | 0.190 |
Why?
|
Mathematics | 1 | 2021 | 31 | 0.190 |
Why?
|
Religious Personnel | 2 | 2018 | 11 | 0.190 |
Why?
|
Axons | 3 | 2020 | 38 | 0.190 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2020 | 5 | 0.190 |
Why?
|
Actinin | 1 | 2020 | 7 | 0.190 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2020 | 11 | 0.190 |
Why?
|
Writing | 1 | 2021 | 20 | 0.190 |
Why?
|
Apolipoprotein C-I | 1 | 2020 | 2 | 0.190 |
Why?
|
Ribonucleases | 1 | 2020 | 9 | 0.190 |
Why?
|
Inflammation Mediators | 1 | 2021 | 80 | 0.190 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 6 | 0.190 |
Why?
|
CREB-Binding Protein | 2 | 2020 | 4 | 0.180 |
Why?
|
Chronobiology Disorders | 1 | 2020 | 14 | 0.180 |
Why?
|
Muscle Proteins | 2 | 2018 | 30 | 0.180 |
Why?
|
Healthy Aging | 1 | 2020 | 13 | 0.180 |
Why?
|
Sexual Partners | 1 | 2020 | 16 | 0.180 |
Why?
|
Principal Component Analysis | 3 | 2021 | 26 | 0.180 |
Why?
|
Pituitary Hormones | 1 | 2020 | 1 | 0.180 |
Why?
|
Knee Joint | 2 | 2019 | 800 | 0.180 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 2 | 2017 | 4 | 0.180 |
Why?
|
Calcineurin | 1 | 2020 | 8 | 0.180 |
Why?
|
Mass Spectrometry | 5 | 2022 | 41 | 0.180 |
Why?
|
Neuronal Plasticity | 5 | 2019 | 43 | 0.180 |
Why?
|
Counseling | 1 | 2020 | 47 | 0.180 |
Why?
|
NFATC Transcription Factors | 1 | 2020 | 15 | 0.180 |
Why?
|
RNA-Binding Proteins | 3 | 2019 | 24 | 0.180 |
Why?
|
Healthy Lifestyle | 1 | 2020 | 28 | 0.180 |
Why?
|
Education | 5 | 2006 | 40 | 0.180 |
Why?
|
Cerebrospinal Fluid | 1 | 2020 | 19 | 0.180 |
Why?
|
Genotyping Techniques | 2 | 2017 | 10 | 0.180 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2020 | 5 | 0.180 |
Why?
|
Pituitary Neoplasms | 1 | 2020 | 20 | 0.180 |
Why?
|
Herpesvirus 6, Human | 1 | 2020 | 4 | 0.180 |
Why?
|
Blood | 1 | 2020 | 25 | 0.180 |
Why?
|
Flavonols | 1 | 2020 | 6 | 0.180 |
Why?
|
Fragaria | 1 | 2019 | 1 | 0.180 |
Why?
|
Blood-Brain Barrier | 1 | 2020 | 43 | 0.180 |
Why?
|
Organ Specificity | 5 | 2020 | 49 | 0.180 |
Why?
|
Dendritic Spines | 2 | 2017 | 12 | 0.180 |
Why?
|
Inbreeding Depression | 1 | 2019 | 1 | 0.180 |
Why?
|
Perceptual Disorders | 2 | 2012 | 7 | 0.180 |
Why?
|
Health Equity | 1 | 2020 | 17 | 0.170 |
Why?
|
Consanguinity | 1 | 2019 | 4 | 0.170 |
Why?
|
Spliceosomes | 1 | 2019 | 1 | 0.170 |
Why?
|
Fertility | 1 | 2019 | 19 | 0.170 |
Why?
|
Biomarkers, Tumor | 2 | 2015 | 198 | 0.170 |
Why?
|
Cholinesterase Inhibitors | 1 | 2019 | 16 | 0.170 |
Why?
|
Health Surveys | 4 | 2013 | 96 | 0.170 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2019 | 23 | 0.170 |
Why?
|
14-3-3 Proteins | 1 | 2019 | 4 | 0.170 |
Why?
|
Memantine | 1 | 2019 | 13 | 0.170 |
Why?
|
Treatment Outcome | 7 | 2017 | 3561 | 0.170 |
Why?
|
Adipokines | 1 | 2019 | 8 | 0.170 |
Why?
|
Sex Chromosomes | 1 | 2019 | 3 | 0.170 |
Why?
|
Mosaicism | 1 | 2019 | 9 | 0.170 |
Why?
|
Problem Solving | 1 | 2020 | 47 | 0.170 |
Why?
|
Occipital Lobe | 1 | 2019 | 13 | 0.170 |
Why?
|
Amyloidogenic Proteins | 2 | 2017 | 3 | 0.170 |
Why?
|
Ethylene Glycols | 3 | 2017 | 10 | 0.170 |
Why?
|
Spatial Behavior | 2 | 2012 | 14 | 0.170 |
Why?
|
Dinucleoside Phosphates | 1 | 2019 | 1 | 0.170 |
Why?
|
Neurocognitive Disorders | 1 | 2019 | 19 | 0.170 |
Why?
|
Glycoproteins | 4 | 2020 | 57 | 0.170 |
Why?
|
Hip Fractures | 1 | 2019 | 33 | 0.170 |
Why?
|
Models, Theoretical | 1 | 2020 | 94 | 0.170 |
Why?
|
Lung Diseases | 1 | 2019 | 46 | 0.170 |
Why?
|
Mucin-1 | 1 | 2019 | 1 | 0.170 |
Why?
|
Monocytes | 3 | 2017 | 111 | 0.170 |
Why?
|
Ubiquitin | 3 | 2010 | 26 | 0.170 |
Why?
|
Cytokines | 1 | 2021 | 350 | 0.170 |
Why?
|
Body Fluid Compartments | 1 | 2019 | 4 | 0.170 |
Why?
|
Databases, Genetic | 4 | 2021 | 11 | 0.170 |
Why?
|
Markov Chains | 2 | 2018 | 29 | 0.170 |
Why?
|
Immunity | 1 | 2019 | 24 | 0.170 |
Why?
|
Tuberous Sclerosis | 2 | 2017 | 14 | 0.160 |
Why?
|
Down Syndrome | 1 | 2019 | 10 | 0.160 |
Why?
|
Forkhead Transcription Factors | 2 | 2019 | 19 | 0.160 |
Why?
|
Lipids | 1 | 2019 | 36 | 0.160 |
Why?
|
Genetic Linkage | 2 | 2017 | 42 | 0.160 |
Why?
|
Essential Tremor | 1 | 2019 | 17 | 0.160 |
Why?
|
Indoles | 1 | 2019 | 51 | 0.160 |
Why?
|
Glycogen Synthase Kinase 3 | 2 | 2015 | 11 | 0.160 |
Why?
|
Cues | 2 | 2012 | 61 | 0.160 |
Why?
|
Lateral Ventricles | 1 | 2018 | 7 | 0.160 |
Why?
|
Calpain | 1 | 2018 | 2 | 0.160 |
Why?
|
Trinucleotide Repeat Expansion | 2 | 2020 | 47 | 0.160 |
Why?
|
Emergencies | 1 | 2019 | 39 | 0.160 |
Why?
|
E2F Transcription Factors | 1 | 2018 | 5 | 0.160 |
Why?
|
Claudins | 1 | 2018 | 5 | 0.160 |
Why?
|
Suprachiasmatic Nucleus | 2 | 2015 | 15 | 0.160 |
Why?
|
Serpins | 1 | 2018 | 4 | 0.160 |
Why?
|
Muscle Strength Dynamometer | 2 | 2009 | 16 | 0.160 |
Why?
|
DNA Transposable Elements | 1 | 2018 | 2 | 0.160 |
Why?
|
Osteoarthritis | 1 | 2023 | 366 | 0.160 |
Why?
|
Alcoholism | 1 | 2019 | 83 | 0.160 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2018 | 15 | 0.160 |
Why?
|
Parents | 2 | 2012 | 106 | 0.160 |
Why?
|
Estradiol | 1 | 2018 | 47 | 0.160 |
Why?
|
Fishes | 1 | 2018 | 4 | 0.160 |
Why?
|
Adipose Tissue | 1 | 2019 | 74 | 0.160 |
Why?
|
Task Performance and Analysis | 2 | 2016 | 55 | 0.160 |
Why?
|
Toll-Like Receptor 2 | 1 | 2018 | 32 | 0.160 |
Why?
|
Feeding Behavior | 2 | 2016 | 99 | 0.160 |
Why?
|
Cell Adhesion Molecules | 2 | 2015 | 40 | 0.150 |
Why?
|
Boston | 6 | 2021 | 28 | 0.150 |
Why?
|
Epidemiology | 1 | 2018 | 5 | 0.150 |
Why?
|
Phytochemicals | 1 | 2017 | 3 | 0.150 |
Why?
|
Plant Leaves | 1 | 2017 | 3 | 0.150 |
Why?
|
Iodide Peroxidase | 1 | 2018 | 34 | 0.150 |
Why?
|
Population Health | 1 | 2018 | 5 | 0.150 |
Why?
|
Protein-Arginine Deiminases | 1 | 2017 | 11 | 0.150 |
Why?
|
Vegetables | 1 | 2017 | 15 | 0.150 |
Why?
|
alpha-Macroglobulins | 1 | 2017 | 12 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2017 | 12 | 0.150 |
Why?
|
Glucosylceramidase | 2 | 2021 | 26 | 0.150 |
Why?
|
Fragile X Mental Retardation Protein | 2 | 2020 | 117 | 0.150 |
Why?
|
Precision Medicine | 1 | 2018 | 26 | 0.150 |
Why?
|
Neurosciences | 1 | 2018 | 10 | 0.150 |
Why?
|
Homocysteine | 1 | 2017 | 8 | 0.150 |
Why?
|
Enzyme Activation | 6 | 2021 | 112 | 0.150 |
Why?
|
Personality Assessment | 3 | 2006 | 40 | 0.150 |
Why?
|
Transglutaminases | 2 | 2015 | 4 | 0.150 |
Why?
|
Religion and Psychology | 2 | 2010 | 24 | 0.150 |
Why?
|
GTP-Binding Proteins | 2 | 2015 | 11 | 0.150 |
Why?
|
Antidepressive Agents | 1 | 2018 | 103 | 0.150 |
Why?
|
Actins | 1 | 2017 | 45 | 0.150 |
Why?
|
Pseudogenes | 1 | 2017 | 2 | 0.150 |
Why?
|
Protective Factors | 4 | 2020 | 17 | 0.150 |
Why?
|
Thinness | 1 | 2017 | 4 | 0.150 |
Why?
|
Phospholipase C gamma | 1 | 2017 | 9 | 0.150 |
Why?
|
RNA, Untranslated | 1 | 2017 | 3 | 0.150 |
Why?
|
Nurse Clinicians | 1 | 1997 | 26 | 0.150 |
Why?
|
Basal Nucleus of Meynert | 3 | 2002 | 7 | 0.150 |
Why?
|
Fragile X Syndrome | 1 | 2020 | 189 | 0.150 |
Why?
|
Sexual Behavior | 1 | 2017 | 67 | 0.150 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2005 | 3 | 0.150 |
Why?
|
Sensation | 1 | 2017 | 17 | 0.150 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2017 | 3 | 0.150 |
Why?
|
Central Nervous System | 2 | 2017 | 56 | 0.150 |
Why?
|
Glutamic Acid | 3 | 2007 | 32 | 0.140 |
Why?
|
Functional Food | 1 | 2017 | 2 | 0.140 |
Why?
|
Olfactory Cortex | 1 | 2016 | 1 | 0.140 |
Why?
|
Family Conflict | 1 | 2016 | 3 | 0.140 |
Why?
|
Synaptic Transmission | 3 | 2019 | 46 | 0.140 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2016 | 9 | 0.140 |
Why?
|
HIV-1 | 1 | 2020 | 451 | 0.140 |
Why?
|
Organic Anion Transporters, Sodium-Dependent | 1 | 2016 | 3 | 0.140 |
Why?
|
Symporters | 1 | 2016 | 4 | 0.140 |
Why?
|
Ascorbic Acid | 4 | 2020 | 33 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2017 | 78 | 0.140 |
Why?
|
Immunity, Innate | 1 | 2017 | 90 | 0.140 |
Why?
|
Axonal Transport | 1 | 2016 | 8 | 0.140 |
Why?
|
Personality Development | 1 | 2016 | 6 | 0.140 |
Why?
|
Dietary Supplements | 2 | 2015 | 53 | 0.140 |
Why?
|
Subcellular Fractions | 2 | 2008 | 16 | 0.140 |
Why?
|
Receptors, LDL | 2 | 2007 | 7 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 55 | 0.140 |
Why?
|
Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.140 |
Why?
|
Pattern Recognition, Visual | 3 | 2005 | 31 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 194 | 0.140 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2017 | 14 | 0.140 |
Why?
|
Zinc Fingers | 1 | 2016 | 10 | 0.140 |
Why?
|
Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2016 | 1 | 0.140 |
Why?
|
Practice Guidelines as Topic | 2 | 2011 | 334 | 0.140 |
Why?
|
Visual Acuity | 2 | 2007 | 46 | 0.140 |
Why?
|
Vital Capacity | 3 | 2022 | 10 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2016 | 7 | 0.140 |
Why?
|
Mice, Knockout | 3 | 2023 | 309 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 177 | 0.140 |
Why?
|
Glial Fibrillary Acidic Protein | 3 | 2012 | 30 | 0.140 |
Why?
|
Biostatistics | 1 | 2016 | 6 | 0.140 |
Why?
|
Receptor, Melatonin, MT1 | 1 | 2016 | 1 | 0.140 |
Why?
|
Oligonucleotides, Antisense | 1 | 2016 | 13 | 0.140 |
Why?
|
Vulnerable Populations | 1 | 2016 | 24 | 0.140 |
Why?
|
Electroencephalography | 2 | 2014 | 142 | 0.140 |
Why?
|
Mercury | 1 | 2016 | 9 | 0.130 |
Why?
|
Somatoform Disorders | 1 | 2016 | 20 | 0.130 |
Why?
|
Fetus | 1 | 2016 | 56 | 0.130 |
Why?
|
Autoantibodies | 1 | 2016 | 103 | 0.130 |
Why?
|
Munc18 Proteins | 1 | 2015 | 3 | 0.130 |
Why?
|
GABAergic Neurons | 1 | 2015 | 6 | 0.130 |
Why?
|
Whole Genome Sequencing | 3 | 2021 | 5 | 0.130 |
Why?
|
Homes for the Aged | 1 | 2015 | 9 | 0.130 |
Why?
|
Gastrointestinal Microbiome | 1 | 2018 | 181 | 0.130 |
Why?
|
Exosomes | 1 | 2015 | 4 | 0.130 |
Why?
|
Neuroprotective Agents | 3 | 2015 | 60 | 0.130 |
Why?
|
Protein Aggregation, Pathological | 1 | 2015 | 5 | 0.130 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2015 | 1 | 0.130 |
Why?
|
Interleukin-1 Receptor Accessory Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
Cerebrovascular Circulation | 1 | 2016 | 44 | 0.130 |
Why?
|
Receptors, Dopamine D2 | 1 | 2015 | 18 | 0.130 |
Why?
|
Mendelian Randomization Analysis | 3 | 2021 | 7 | 0.130 |
Why?
|
Micronutrients | 1 | 2015 | 4 | 0.130 |
Why?
|
Food, Formulated | 1 | 2015 | 6 | 0.130 |
Why?
|
Plasma | 1 | 2015 | 34 | 0.130 |
Why?
|
Adiposity | 1 | 2016 | 47 | 0.130 |
Why?
|
Computer Simulation | 6 | 2020 | 218 | 0.130 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2015 | 3 | 0.130 |
Why?
|
Lumbar Vertebrae | 2 | 2018 | 490 | 0.130 |
Why?
|
Cholinergic Antagonists | 2 | 2013 | 13 | 0.130 |
Why?
|
Visceral Afferents | 1 | 2015 | 4 | 0.130 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 3 | 2014 | 34 | 0.130 |
Why?
|
Spinal Cord Dorsal Horn | 1 | 2015 | 8 | 0.130 |
Why?
|
Presynaptic Terminals | 3 | 2016 | 16 | 0.130 |
Why?
|
Bias | 3 | 2016 | 34 | 0.130 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 36 | 0.130 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 20 | 0.130 |
Why?
|
HMGN1 Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
Fractals | 3 | 2019 | 22 | 0.130 |
Why?
|
DNA Mutational Analysis | 3 | 2012 | 57 | 0.130 |
Why?
|
Serine Endopeptidases | 2 | 2017 | 16 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 107 | 0.130 |
Why?
|
Caspases | 2 | 2005 | 33 | 0.130 |
Why?
|
Synucleins | 2 | 2013 | 8 | 0.120 |
Why?
|
Early Diagnosis | 4 | 2020 | 66 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-fyn | 2 | 2012 | 3 | 0.120 |
Why?
|
Nootropic Agents | 1 | 2015 | 12 | 0.120 |
Why?
|
Life Change Events | 1 | 2014 | 36 | 0.120 |
Why?
|
Event-Related Potentials, P300 | 1 | 2014 | 2 | 0.120 |
Why?
|
Multiple System Atrophy | 1 | 2015 | 42 | 0.120 |
Why?
|
Receptor, EphA1 | 2 | 2012 | 4 | 0.120 |
Why?
|
A Kinase Anchor Proteins | 1 | 2014 | 2 | 0.120 |
Why?
|
Preoptic Area | 1 | 2014 | 6 | 0.120 |
Why?
|
Acetylcholine | 3 | 2005 | 12 | 0.120 |
Why?
|
Empathy | 1 | 2014 | 36 | 0.120 |
Why?
|
Epidemiologic Research Design | 2 | 2012 | 16 | 0.120 |
Why?
|
DNA | 2 | 2023 | 122 | 0.120 |
Why?
|
Protein Array Analysis | 2 | 2012 | 10 | 0.120 |
Why?
|
Sensation Disorders | 1 | 2014 | 13 | 0.120 |
Why?
|
Metabolic Syndrome | 1 | 2015 | 68 | 0.120 |
Why?
|
Sulfonylurea Receptors | 1 | 2014 | 3 | 0.120 |
Why?
|
Glucuronidase | 1 | 2014 | 11 | 0.120 |
Why?
|
Obesity | 3 | 2015 | 290 | 0.120 |
Why?
|
Neuroglia | 3 | 2018 | 39 | 0.120 |
Why?
|
Troponin T | 1 | 2014 | 4 | 0.120 |
Why?
|
Image Enhancement | 2 | 2013 | 57 | 0.120 |
Why?
|
Erythrocyte Indices | 1 | 2014 | 5 | 0.120 |
Why?
|
Transcription Factor RelA | 1 | 2014 | 14 | 0.120 |
Why?
|
gamma-Tocopherol | 1 | 2014 | 7 | 0.120 |
Why?
|
alpha-Tocopherol | 1 | 2014 | 9 | 0.120 |
Why?
|
Preventive Medicine | 1 | 2014 | 12 | 0.120 |
Why?
|
Patient Admission | 1 | 2014 | 30 | 0.120 |
Why?
|
Neuropil Threads | 3 | 2007 | 4 | 0.120 |
Why?
|
Raphe Nuclei | 1 | 2013 | 8 | 0.120 |
Why?
|
Ventral Tegmental Area | 1 | 2013 | 12 | 0.120 |
Why?
|
Meta-Analysis as Topic | 4 | 2016 | 40 | 0.120 |
Why?
|
Medicare Part D | 1 | 2013 | 7 | 0.110 |
Why?
|
Blood Loss, Surgical | 1 | 2014 | 66 | 0.110 |
Why?
|
Telemetry | 1 | 2013 | 11 | 0.110 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 44 | 0.110 |
Why?
|
Delusions | 2 | 2005 | 12 | 0.110 |
Why?
|
Inheritance Patterns | 1 | 2013 | 6 | 0.110 |
Why?
|
p21-Activated Kinases | 1 | 2013 | 7 | 0.110 |
Why?
|
Patient Selection | 2 | 2012 | 234 | 0.110 |
Why?
|
Accidents, Traffic | 2 | 2012 | 14 | 0.110 |
Why?
|
Hospital Mortality | 1 | 2014 | 140 | 0.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 58 | 0.110 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2013 | 5 | 0.110 |
Why?
|
China | 3 | 2019 | 58 | 0.110 |
Why?
|
Microcirculation | 2 | 2011 | 39 | 0.110 |
Why?
|
PrPC Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
Carbamazepine | 2 | 2005 | 13 | 0.110 |
Why?
|
Mood Disorders | 2 | 2005 | 29 | 0.110 |
Why?
|
Recombinant Proteins | 5 | 2017 | 258 | 0.110 |
Why?
|
Epilepsies, Partial | 2 | 2005 | 24 | 0.110 |
Why?
|
Artifacts | 2 | 2023 | 34 | 0.110 |
Why?
|
Time Perception | 1 | 2012 | 6 | 0.110 |
Why?
|
Myocardial Infarction | 1 | 2014 | 175 | 0.110 |
Why?
|
Fear | 2 | 2017 | 47 | 0.110 |
Why?
|
Menopause | 1 | 2013 | 135 | 0.110 |
Why?
|
R-SNARE Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2012 | 5 | 0.100 |
Why?
|
Nerve Regeneration | 1 | 2012 | 14 | 0.100 |
Why?
|
Cyclic AMP | 1 | 2012 | 25 | 0.100 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2012 | 12 | 0.100 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2012 | 4 | 0.100 |
Why?
|
Licensure | 1 | 2012 | 9 | 0.100 |
Why?
|
Eicosapentaenoic Acid | 3 | 2022 | 8 | 0.100 |
Why?
|
Selection, Genetic | 1 | 2012 | 6 | 0.100 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2012 | 29 | 0.100 |
Why?
|
Caspase 3 | 2 | 2010 | 30 | 0.100 |
Why?
|
Bipolar Disorder | 3 | 2017 | 105 | 0.100 |
Why?
|
Receptors, Complement | 1 | 2012 | 5 | 0.100 |
Why?
|
Leukotriene B4 | 2 | 2022 | 5 | 0.100 |
Why?
|
Environment | 1 | 2012 | 47 | 0.100 |
Why?
|
Anticonvulsants | 2 | 2005 | 111 | 0.100 |
Why?
|
Games, Experimental | 1 | 2011 | 9 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2011 | 18 | 0.100 |
Why?
|
Likelihood Functions | 3 | 2017 | 27 | 0.100 |
Why?
|
Sequence Analysis, DNA | 3 | 2020 | 73 | 0.100 |
Why?
|
Endocytosis | 1 | 2011 | 17 | 0.100 |
Why?
|
Spinal Cord Injuries | 1 | 2012 | 48 | 0.100 |
Why?
|
Multigene Family | 3 | 2018 | 11 | 0.100 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 53 | 0.100 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2012 | 58 | 0.100 |
Why?
|
Phlebotomy | 1 | 2011 | 4 | 0.100 |
Why?
|
Transfection | 4 | 2013 | 130 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 1 | 2013 | 222 | 0.100 |
Why?
|
Cerebral Angiography | 1 | 2011 | 30 | 0.100 |
Why?
|
Guanylate Kinases | 1 | 2011 | 2 | 0.100 |
Why?
|
Post-Synaptic Density | 1 | 2011 | 2 | 0.100 |
Why?
|
Corticosterone | 1 | 2011 | 3 | 0.100 |
Why?
|
Carnitine | 2 | 2022 | 8 | 0.100 |
Why?
|
Receptor, trkA | 2 | 2001 | 9 | 0.100 |
Why?
|
Aspirin | 2 | 2008 | 84 | 0.100 |
Why?
|
Antibodies | 1 | 2011 | 66 | 0.100 |
Why?
|
Peptidylprolyl Isomerase | 2 | 2010 | 6 | 0.100 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 16 | 0.100 |
Why?
|
Absorptiometry, Photon | 2 | 2023 | 84 | 0.100 |
Why?
|
gamma-Aminobutyric Acid | 2 | 2015 | 49 | 0.100 |
Why?
|
Intensive Care Units | 1 | 2014 | 312 | 0.100 |
Why?
|
Glucose | 3 | 2022 | 60 | 0.100 |
Why?
|
Population Dynamics | 3 | 2011 | 11 | 0.100 |
Why?
|
Europe | 2 | 2021 | 85 | 0.100 |
Why?
|
Parahippocampal Gyrus | 2 | 2002 | 8 | 0.100 |
Why?
|
Wakefulness | 1 | 2011 | 80 | 0.100 |
Why?
|
Terahertz Imaging | 1 | 2011 | 1 | 0.100 |
Why?
|
Cerebral Ventricles | 1 | 2011 | 23 | 0.090 |
Why?
|
Antigens, CD | 1 | 2011 | 102 | 0.090 |
Why?
|
Semantics | 2 | 2008 | 20 | 0.090 |
Why?
|
Lysosomes | 2 | 2021 | 24 | 0.090 |
Why?
|
Insulysin | 1 | 2010 | 1 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 155 | 0.090 |
Why?
|
Cell Cycle | 1 | 2010 | 38 | 0.090 |
Why?
|
Metalloendopeptidases | 1 | 2010 | 25 | 0.090 |
Why?
|
Species Specificity | 2 | 2020 | 73 | 0.090 |
Why?
|
Fitness Trackers | 2 | 2021 | 14 | 0.090 |
Why?
|
Pilot Projects | 3 | 2020 | 403 | 0.090 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2010 | 2 | 0.090 |
Why?
|
Adenosine Triphosphatases | 1 | 2010 | 7 | 0.090 |
Why?
|
Telephone | 1 | 2010 | 27 | 0.090 |
Why?
|
CA3 Region, Hippocampal | 1 | 2010 | 7 | 0.090 |
Why?
|
Medical History Taking | 2 | 2020 | 24 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2010 | 16 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 143 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 2 | 1994 | 778 | 0.090 |
Why?
|
Electric Impedance | 2 | 2021 | 25 | 0.090 |
Why?
|
Single-Blind Method | 4 | 2014 | 120 | 0.090 |
Why?
|
Atlases as Topic | 2 | 2021 | 7 | 0.090 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2010 | 5 | 0.090 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 2 | 2021 | 10 | 0.090 |
Why?
|
Synaptic Vesicles | 2 | 2020 | 4 | 0.090 |
Why?
|
Intelligence Tests | 2 | 2021 | 15 | 0.090 |
Why?
|
Antibodies, Monoclonal | 5 | 2008 | 270 | 0.090 |
Why?
|
Neurogenesis | 2 | 2020 | 11 | 0.090 |
Why?
|
Cost of Illness | 2 | 2020 | 55 | 0.090 |
Why?
|
Adrenergic beta-Agonists | 1 | 2009 | 19 | 0.090 |
Why?
|
Drug Design | 1 | 2009 | 31 | 0.090 |
Why?
|
Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 165 | 0.090 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2010 | 29 | 0.090 |
Why?
|
Vasodilator Agents | 1 | 2009 | 33 | 0.090 |
Why?
|
Exome | 2 | 2021 | 8 | 0.090 |
Why?
|
Ambulatory Care Facilities | 2 | 2006 | 37 | 0.090 |
Why?
|
Sterols | 1 | 2009 | 5 | 0.090 |
Why?
|
Mechanoreceptors | 1 | 2009 | 7 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2020 | 11 | 0.080 |
Why?
|
Molecular Biology | 1 | 2009 | 14 | 0.080 |
Why?
|
Alcohol Drinking | 2 | 2020 | 77 | 0.080 |
Why?
|
Proprioception | 1 | 2009 | 19 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 59 | 0.080 |
Why?
|
Dystonia | 1 | 1989 | 54 | 0.080 |
Why?
|
Cytoplasm | 2 | 2010 | 37 | 0.080 |
Why?
|
Formaldehyde | 1 | 2009 | 14 | 0.080 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1989 | 48 | 0.080 |
Why?
|
Sirtuins | 1 | 2009 | 1 | 0.080 |
Why?
|
Immunoprecipitation | 3 | 2014 | 23 | 0.080 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 32 | 0.080 |
Why?
|
Gene Expression Regulation, Developmental | 2 | 2019 | 32 | 0.080 |
Why?
|
Dopamine | 1 | 2009 | 161 | 0.080 |
Why?
|
Ergometry | 1 | 2008 | 3 | 0.080 |
Why?
|
Differential Threshold | 1 | 2008 | 3 | 0.080 |
Why?
|
Joints | 1 | 2009 | 99 | 0.080 |
Why?
|
Nervous System | 1 | 1988 | 10 | 0.080 |
Why?
|
Dendrites | 2 | 2010 | 15 | 0.080 |
Why?
|
Extremities | 1 | 2008 | 33 | 0.080 |
Why?
|
ADAMTS Proteins | 2 | 2019 | 5 | 0.080 |
Why?
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2019 | 5 | 0.080 |
Why?
|
Claudin-5 | 2 | 2021 | 3 | 0.080 |
Why?
|
Cell Differentiation | 2 | 2020 | 149 | 0.080 |
Why?
|
Versicans | 2 | 2019 | 17 | 0.080 |
Why?
|
Primary Cell Culture | 2 | 2018 | 21 | 0.080 |
Why?
|
Physical Therapy Modalities | 2 | 2022 | 81 | 0.080 |
Why?
|
Complement C9 | 1 | 2008 | 1 | 0.080 |
Why?
|
Complement C3b | 1 | 2008 | 2 | 0.080 |
Why?
|
Healthy Volunteers | 2 | 2021 | 46 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2008 | 21 | 0.080 |
Why?
|
Carbon-Nitrogen Lyases | 1 | 2008 | 2 | 0.080 |
Why?
|
Cell Line | 2 | 2019 | 299 | 0.080 |
Why?
|
Microarray Analysis | 2 | 2019 | 8 | 0.080 |
Why?
|
Encephalitis | 1 | 2008 | 18 | 0.080 |
Why?
|
Chromosomes, Human, Pair 18 | 2 | 2020 | 6 | 0.080 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 32 | 0.080 |
Why?
|
Hypercholesterolemia | 1 | 2008 | 29 | 0.080 |
Why?
|
Intracranial Hemorrhages | 1 | 2008 | 14 | 0.080 |
Why?
|
Respiratory Insufficiency | 1 | 1988 | 50 | 0.080 |
Why?
|
In Vitro Techniques | 3 | 2020 | 215 | 0.070 |
Why?
|
Pedigree | 3 | 2016 | 65 | 0.070 |
Why?
|
Gene Knockdown Techniques | 2 | 2019 | 42 | 0.070 |
Why?
|
Mass Screening | 1 | 2009 | 180 | 0.070 |
Why?
|
Receptors, Erythropoietin | 1 | 2007 | 2 | 0.070 |
Why?
|
Rats, Sprague-Dawley | 2 | 2021 | 463 | 0.070 |
Why?
|
Cholesterol | 2 | 2022 | 54 | 0.070 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
Chemical Fractionation | 2 | 2004 | 7 | 0.070 |
Why?
|
Long-Term Care | 1 | 2007 | 56 | 0.070 |
Why?
|
Protein Conformation | 3 | 2016 | 70 | 0.070 |
Why?
|
Observation | 1 | 2007 | 16 | 0.070 |
Why?
|
Frontotemporal Dementia | 2 | 2019 | 14 | 0.070 |
Why?
|
Health Planning | 1 | 2007 | 5 | 0.070 |
Why?
|
Genetic Markers | 2 | 2020 | 45 | 0.070 |
Why?
|
Lipase | 1 | 2006 | 5 | 0.070 |
Why?
|
Exercise Tolerance | 1 | 2007 | 32 | 0.070 |
Why?
|
Psychotropic Drugs | 1 | 2007 | 23 | 0.070 |
Why?
|
Lipid Bilayers | 3 | 1991 | 55 | 0.070 |
Why?
|
Anesthetics | 3 | 1991 | 25 | 0.070 |
Why?
|
Selenium | 2 | 2017 | 7 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2022 | 60 | 0.070 |
Why?
|
Cellular Senescence | 2 | 2019 | 18 | 0.070 |
Why?
|
Molecular Sequence Annotation | 2 | 2016 | 6 | 0.070 |
Why?
|
Interneurons | 1 | 2006 | 6 | 0.070 |
Why?
|
Caenorhabditis elegans | 2 | 2019 | 7 | 0.070 |
Why?
|
Nerve Fibers | 1 | 2006 | 15 | 0.070 |
Why?
|
Urban Health | 1 | 2006 | 23 | 0.070 |
Why?
|
Parent-Child Relations | 1 | 2006 | 34 | 0.070 |
Why?
|
Biotechnology | 1 | 2005 | 3 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2014 | 696 | 0.070 |
Why?
|
Photic Stimulation | 1 | 2005 | 45 | 0.070 |
Why?
|
Sweden | 2 | 2016 | 9 | 0.070 |
Why?
|
Glycogen Synthase Kinase 3 beta | 2 | 2015 | 15 | 0.070 |
Why?
|
Leukemia, Myeloid | 1 | 2005 | 6 | 0.060 |
Why?
|
Transplantation Conditioning | 1 | 2005 | 35 | 0.060 |
Why?
|
Confusion | 1 | 2005 | 13 | 0.060 |
Why?
|
Binding Sites | 2 | 2017 | 76 | 0.060 |
Why?
|
Animals, Genetically Modified | 2 | 2018 | 17 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 1 | 2005 | 38 | 0.060 |
Why?
|
Practice Patterns, Physicians' | 1 | 2006 | 129 | 0.060 |
Why?
|
Exons | 3 | 2013 | 37 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 2 | 2017 | 76 | 0.060 |
Why?
|
Pregnancy | 2 | 2020 | 388 | 0.060 |
Why?
|
Visual Cortex | 1 | 2005 | 8 | 0.060 |
Why?
|
Parenting | 1 | 2006 | 72 | 0.060 |
Why?
|
Family Characteristics | 1 | 2005 | 20 | 0.060 |
Why?
|
Alzheimer Vaccines | 1 | 2005 | 1 | 0.060 |
Why?
|
Introns | 2 | 2015 | 16 | 0.060 |
Why?
|
Body Weight | 1 | 2005 | 132 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2005 | 40 | 0.060 |
Why?
|
Logic | 1 | 2004 | 3 | 0.060 |
Why?
|
Microsomes | 1 | 2004 | 18 | 0.060 |
Why?
|
Neurites | 3 | 2010 | 12 | 0.060 |
Why?
|
Maze Learning | 2 | 2016 | 17 | 0.060 |
Why?
|
Microscopy, Fluorescence | 3 | 2016 | 89 | 0.060 |
Why?
|
Membrane Microdomains | 1 | 2004 | 15 | 0.060 |
Why?
|
Receptors, GABA-A | 1 | 2004 | 3 | 0.060 |
Why?
|
Fibroblasts | 2 | 2016 | 93 | 0.060 |
Why?
|
Protein Subunits | 1 | 2004 | 21 | 0.060 |
Why?
|
Niacin | 1 | 2004 | 2 | 0.060 |
Why?
|
Institutionalization | 1 | 2004 | 3 | 0.060 |
Why?
|
Superoxide Dismutase | 2 | 2021 | 18 | 0.060 |
Why?
|
Cell Death | 3 | 2014 | 62 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2005 | 90 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2004 | 22 | 0.060 |
Why?
|
Prejudice | 1 | 2004 | 37 | 0.060 |
Why?
|
Auditory Perception | 2 | 2017 | 36 | 0.060 |
Why?
|
Myelin Basic Protein | 1 | 2004 | 14 | 0.060 |
Why?
|
Speech Perception | 1 | 2004 | 48 | 0.060 |
Why?
|
Meninges | 1 | 2023 | 7 | 0.060 |
Why?
|
Software | 2 | 2019 | 72 | 0.060 |
Why?
|
Minority Groups | 2 | 2020 | 67 | 0.060 |
Why?
|
Government Agencies | 1 | 2023 | 4 | 0.060 |
Why?
|
Base Sequence | 1 | 2023 | 133 | 0.060 |
Why?
|
Protein Binding | 2 | 2016 | 125 | 0.060 |
Why?
|
Neurotransmitter Agents | 1 | 2003 | 20 | 0.060 |
Why?
|
Embryo, Mammalian | 2 | 2016 | 30 | 0.060 |
Why?
|
RNA, Small Nuclear | 1 | 2023 | 2 | 0.050 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2023 | 12 | 0.050 |
Why?
|
Dietary Fats | 1 | 2003 | 22 | 0.050 |
Why?
|
5-Methylcytosine | 1 | 2023 | 4 | 0.050 |
Why?
|
Green Fluorescent Proteins | 2 | 2014 | 34 | 0.050 |
Why?
|
Amino Acid Substitution | 2 | 2018 | 25 | 0.050 |
Why?
|
Behavior | 2 | 1994 | 27 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 329 | 0.050 |
Why?
|
Cell Line, Transformed | 2 | 2013 | 17 | 0.050 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2022 | 8 | 0.050 |
Why?
|
Receptors, GABA | 2 | 2017 | 5 | 0.050 |
Why?
|
Copper | 1 | 2022 | 12 | 0.050 |
Why?
|
Ganglia, Spinal | 1 | 2023 | 58 | 0.050 |
Why?
|
Contraindications | 1 | 2002 | 42 | 0.050 |
Why?
|
Macrophages | 1 | 2023 | 128 | 0.050 |
Why?
|
Triglycerides | 1 | 2022 | 45 | 0.050 |
Why?
|
Forced Expiratory Volume | 1 | 2022 | 9 | 0.050 |
Why?
|
Gene Dosage | 2 | 2012 | 24 | 0.050 |
Why?
|
Boronic Acids | 1 | 2022 | 4 | 0.050 |
Why?
|
Protein Multimerization | 2 | 2013 | 18 | 0.050 |
Why?
|
Glycosylation | 1 | 2022 | 24 | 0.050 |
Why?
|
Polysaccharides | 1 | 2022 | 15 | 0.050 |
Why?
|
Bone Density | 1 | 2023 | 151 | 0.050 |
Why?
|
Thoracic Vertebrae | 2 | 2015 | 112 | 0.050 |
Why?
|
Qualitative Research | 1 | 2023 | 113 | 0.050 |
Why?
|
Zebrafish | 1 | 2022 | 19 | 0.050 |
Why?
|
Angiotensin II | 1 | 2022 | 7 | 0.050 |
Why?
|
Unconsciousness | 1 | 2022 | 8 | 0.050 |
Why?
|
Protein Phosphatase 2 | 1 | 2022 | 1 | 0.050 |
Why?
|
Receptor, Nerve Growth Factor | 1 | 2002 | 7 | 0.050 |
Why?
|
Silver Staining | 1 | 2002 | 5 | 0.050 |
Why?
|
Motivation | 1 | 2023 | 101 | 0.050 |
Why?
|
Hydroxysteroid Dehydrogenases | 1 | 2021 | 1 | 0.050 |
Why?
|
Nucleotides | 1 | 2021 | 1 | 0.050 |
Why?
|
Phosphofructokinase-1, Type C | 1 | 2021 | 1 | 0.050 |
Why?
|
Thiazoles | 2 | 2013 | 35 | 0.050 |
Why?
|
Bethanechol Compounds | 2 | 1993 | 6 | 0.050 |
Why?
|
Fruit | 1 | 2022 | 24 | 0.050 |
Why?
|
Retinoid X Receptors | 1 | 2021 | 3 | 0.050 |
Why?
|
Amino Acids | 1 | 2021 | 21 | 0.050 |
Why?
|
Polycomb Repressive Complex 1 | 1 | 2021 | 2 | 0.050 |
Why?
|
Docosahexaenoic Acids | 2 | 2017 | 8 | 0.050 |
Why?
|
Oxylipins | 1 | 2021 | 1 | 0.050 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2021 | 25 | 0.050 |
Why?
|
Endocannabinoids | 1 | 2021 | 3 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 35 | 0.050 |
Why?
|
Caffeine | 1 | 2022 | 64 | 0.050 |
Why?
|
Eating | 1 | 2022 | 46 | 0.050 |
Why?
|
Fasting | 1 | 2021 | 13 | 0.050 |
Why?
|
Arthralgia | 1 | 2023 | 122 | 0.050 |
Why?
|
Cerebral Hemorrhage | 1 | 2023 | 131 | 0.050 |
Why?
|
North America | 1 | 2021 | 39 | 0.050 |
Why?
|
Supervised Machine Learning | 1 | 2021 | 10 | 0.050 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 28 | 0.050 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 18 | 0.050 |
Why?
|
Gene Knock-In Techniques | 1 | 2021 | 9 | 0.050 |
Why?
|
Pharmacoepidemiology | 1 | 2021 | 5 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2022 | 224 | 0.050 |
Why?
|
Endoribonucleases | 1 | 2021 | 1 | 0.050 |
Why?
|
Spatial Processing | 1 | 2021 | 6 | 0.050 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 34 | 0.050 |
Why?
|
Inflammasomes | 1 | 2021 | 15 | 0.050 |
Why?
|
Poly T | 1 | 2021 | 2 | 0.050 |
Why?
|
Acute-Phase Proteins | 1 | 2021 | 14 | 0.050 |
Why?
|
Serotonin | 1 | 2021 | 42 | 0.050 |
Why?
|
HeLa Cells | 1 | 2021 | 52 | 0.050 |
Why?
|
Ion Channels | 1 | 2023 | 190 | 0.050 |
Why?
|
HLA-DQ alpha-Chains | 1 | 2021 | 2 | 0.050 |
Why?
|
Glycolysis | 1 | 2021 | 21 | 0.050 |
Why?
|
Growth Differentiation Factor 5 | 1 | 2021 | 8 | 0.050 |
Why?
|
Receptors, Virus | 1 | 2021 | 7 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2021 | 17 | 0.050 |
Why?
|
New York City | 1 | 2021 | 18 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2021 | 206 | 0.050 |
Why?
|
Myeloid Cells | 1 | 2020 | 16 | 0.050 |
Why?
|
Proteolysis | 1 | 2020 | 13 | 0.050 |
Why?
|
Language Disorders | 1 | 2000 | 10 | 0.050 |
Why?
|
Attitude to Death | 1 | 2020 | 14 | 0.050 |
Why?
|
Rats, Transgenic | 1 | 2020 | 21 | 0.050 |
Why?
|
HLA-DRB1 Chains | 1 | 2020 | 4 | 0.050 |
Why?
|
Y Chromosome | 1 | 2020 | 1 | 0.050 |
Why?
|
X Chromosome | 1 | 2020 | 9 | 0.050 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 34 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2020 | 12 | 0.050 |
Why?
|
Observer Variation | 2 | 1997 | 119 | 0.050 |
Why?
|
Testis | 1 | 2020 | 12 | 0.050 |
Why?
|
Late Onset Disorders | 1 | 2020 | 6 | 0.050 |
Why?
|
NF-kappa B | 1 | 2021 | 110 | 0.050 |
Why?
|
Behavior, Animal | 1 | 2021 | 107 | 0.050 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 34 | 0.050 |
Why?
|
Craniopharyngioma | 1 | 2020 | 4 | 0.050 |
Why?
|
Sphenoid Bone | 1 | 2020 | 5 | 0.050 |
Why?
|
Sella Turcica | 1 | 2020 | 5 | 0.050 |
Why?
|
Cell Culture Techniques | 1 | 2020 | 45 | 0.050 |
Why?
|
Carotenoids | 1 | 2020 | 8 | 0.050 |
Why?
|
Vertigo | 1 | 2000 | 8 | 0.050 |
Why?
|
Myelin Sheath | 1 | 2020 | 18 | 0.050 |
Why?
|
Skull | 1 | 2020 | 25 | 0.040 |
Why?
|
Protein Transport | 2 | 2011 | 39 | 0.040 |
Why?
|
Meningioma | 1 | 2020 | 18 | 0.040 |
Why?
|
POU Domain Factors | 1 | 2020 | 2 | 0.040 |
Why?
|
Sample Size | 1 | 2020 | 25 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2017 | 195 | 0.040 |
Why?
|
Kaempferols | 1 | 2020 | 7 | 0.040 |
Why?
|
Quercetin | 1 | 2020 | 10 | 0.040 |
Why?
|
Machine Learning | 1 | 2020 | 54 | 0.040 |
Why?
|
Flavonoids | 1 | 2020 | 19 | 0.040 |
Why?
|
Aggression | 2 | 2004 | 30 | 0.040 |
Why?
|
Red Meat | 1 | 2020 | 1 | 0.040 |
Why?
|
Cheese | 1 | 2020 | 1 | 0.040 |
Why?
|
Sodium Chloride, Dietary | 1 | 2020 | 1 | 0.040 |
Why?
|
Amyloid Neuropathies | 1 | 2020 | 4 | 0.040 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 5 | 0.040 |
Why?
|
Wine | 1 | 2020 | 8 | 0.040 |
Why?
|
Permeability | 1 | 2020 | 139 | 0.040 |
Why?
|
Focus Groups | 1 | 2020 | 85 | 0.040 |
Why?
|
Neuropilin-1 | 1 | 2019 | 3 | 0.040 |
Why?
|
Mice, 129 Strain | 1 | 2019 | 2 | 0.040 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2019 | 2 | 0.040 |
Why?
|
Sampling Studies | 3 | 2005 | 29 | 0.040 |
Why?
|
Lung Volume Measurements | 1 | 2019 | 4 | 0.040 |
Why?
|
Substantia Innominata | 1 | 1999 | 3 | 0.040 |
Why?
|
Neovascularization, Physiologic | 1 | 2019 | 21 | 0.040 |
Why?
|
Oligodendroglia | 1 | 2020 | 26 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 1999 | 11 | 0.040 |
Why?
|
Self Concept | 1 | 2020 | 46 | 0.040 |
Why?
|
RNA Interference | 1 | 2019 | 34 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2014 | 53 | 0.040 |
Why?
|
Heredity | 1 | 2019 | 6 | 0.040 |
Why?
|
Random Allocation | 2 | 1999 | 143 | 0.040 |
Why?
|
Aneuploidy | 1 | 2019 | 3 | 0.040 |
Why?
|
Internationality | 1 | 2019 | 24 | 0.040 |
Why?
|
Students | 1 | 2020 | 37 | 0.040 |
Why?
|
Alcohol Dehydrogenase | 1 | 2019 | 1 | 0.040 |
Why?
|
Ventral Striatum | 1 | 2019 | 1 | 0.040 |
Why?
|
Leptin | 1 | 2019 | 23 | 0.040 |
Why?
|
Postoperative Care | 1 | 2020 | 127 | 0.040 |
Why?
|
Nestin | 1 | 2019 | 3 | 0.040 |
Why?
|
SOXB1 Transcription Factors | 1 | 2019 | 4 | 0.040 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2019 | 9 | 0.040 |
Why?
|
Theta Rhythm | 1 | 2019 | 8 | 0.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2019 | 42 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 379 | 0.040 |
Why?
|
Gene Targeting | 1 | 2019 | 10 | 0.040 |
Why?
|
Dopaminergic Neurons | 1 | 2020 | 44 | 0.040 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2019 | 3 | 0.040 |
Why?
|
Sigmoidoscopy | 1 | 1998 | 8 | 0.040 |
Why?
|
Enema | 1 | 1998 | 3 | 0.040 |
Why?
|
Vocabulary | 1 | 1999 | 14 | 0.040 |
Why?
|
Spatial Navigation | 1 | 2018 | 6 | 0.040 |
Why?
|
Systems Integration | 1 | 2018 | 5 | 0.040 |
Why?
|
Diagnostic Techniques, Neurological | 1 | 2018 | 10 | 0.040 |
Why?
|
Systems Biology | 1 | 2018 | 7 | 0.040 |
Why?
|
Time and Motion Studies | 1 | 2018 | 16 | 0.040 |
Why?
|
DNA Repair | 1 | 2018 | 7 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 18 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2018 | 8 | 0.040 |
Why?
|
Home Care Services | 1 | 1998 | 21 | 0.040 |
Why?
|
Acute Disease | 3 | 2005 | 225 | 0.040 |
Why?
|
Reproduction | 1 | 2018 | 12 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 21 | 0.040 |
Why?
|
Phosphoproteins | 1 | 2018 | 28 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2018 | 69 | 0.040 |
Why?
|
Threonine | 1 | 2018 | 7 | 0.040 |
Why?
|
Genetic Pleiotropy | 1 | 2018 | 1 | 0.040 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 9 | 0.040 |
Why?
|
Alanine | 1 | 2018 | 11 | 0.040 |
Why?
|
Language Tests | 2 | 2013 | 29 | 0.040 |
Why?
|
Nutritional Status | 2 | 2011 | 39 | 0.040 |
Why?
|
Gene Library | 1 | 2018 | 8 | 0.040 |
Why?
|
Dysbiosis | 1 | 2018 | 64 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2015 | 522 | 0.040 |
Why?
|
Actin Depolymerizing Factors | 1 | 2017 | 2 | 0.040 |
Why?
|
Cell Polarity | 1 | 2017 | 8 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2013 | 618 | 0.040 |
Why?
|
Conditioning, Classical | 1 | 2017 | 7 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2018 | 26 | 0.040 |
Why?
|
Philadelphia | 1 | 2017 | 5 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2018 | 53 | 0.040 |
Why?
|
Prisoners | 1 | 2017 | 11 | 0.040 |
Why?
|
France | 1 | 2017 | 36 | 0.040 |
Why?
|
Cell Lineage | 1 | 2017 | 31 | 0.040 |
Why?
|
Gene Deletion | 2 | 2012 | 42 | 0.040 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2017 | 2 | 0.040 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2017 | 2 | 0.040 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2017 | 5 | 0.040 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2017 | 45 | 0.040 |
Why?
|
Protein Structure, Quaternary | 1 | 2017 | 8 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2017 | 13 | 0.040 |
Why?
|
Netrin Receptors | 1 | 2017 | 5 | 0.040 |
Why?
|
Solubility | 1 | 2017 | 36 | 0.040 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2017 | 14 | 0.040 |
Why?
|
Research | 1 | 2017 | 55 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2017 | 12 | 0.040 |
Why?
|
Caribbean Region | 1 | 2017 | 4 | 0.040 |
Why?
|
NFI Transcription Factors | 1 | 2017 | 1 | 0.040 |
Why?
|
Peroxisomal Bifunctional Enzyme | 1 | 2017 | 1 | 0.040 |
Why?
|
Heparin-binding EGF-like Growth Factor | 1 | 2017 | 5 | 0.040 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 27 | 0.040 |
Why?
|
Liver | 1 | 2018 | 175 | 0.040 |
Why?
|
Methionine Sulfoxide Reductases | 1 | 2017 | 5 | 0.040 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2016 | 1 | 0.040 |
Why?
|
Polycomb-Group Proteins | 1 | 2016 | 1 | 0.040 |
Why?
|
GTPase-Activating Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
Dipeptidyl Peptidase 4 | 1 | 2017 | 7 | 0.040 |
Why?
|
Vitamins | 1 | 2017 | 16 | 0.040 |
Why?
|
Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 3 | 0.040 |
Why?
|
Vesicular Glutamate Transport Protein 1 | 1 | 2016 | 4 | 0.040 |
Why?
|
Rats, Long-Evans | 1 | 2016 | 13 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2017 | 76 | 0.040 |
Why?
|
Oncogene Protein v-akt | 1 | 2016 | 12 | 0.040 |
Why?
|
Creutzfeldt-Jakob Syndrome | 1 | 1996 | 2 | 0.040 |
Why?
|
p300-CBP Transcription Factors | 1 | 2016 | 2 | 0.030 |
Why?
|
Consciousness Disorders | 1 | 2016 | 12 | 0.030 |
Why?
|
Quantitative Trait, Heritable | 1 | 2016 | 9 | 0.030 |
Why?
|
Monitoring, Ambulatory | 1 | 2016 | 20 | 0.030 |
Why?
|
PubMed | 1 | 2016 | 12 | 0.030 |
Why?
|
Protein Stability | 1 | 2016 | 7 | 0.030 |
Why?
|
Neuroprotection | 1 | 2016 | 3 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 47 | 0.030 |
Why?
|
Protein Folding | 1 | 2016 | 22 | 0.030 |
Why?
|
Neurology | 1 | 1997 | 105 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2017 | 82 | 0.030 |
Why?
|
COS Cells | 1 | 2016 | 38 | 0.030 |
Why?
|
Organic Anion Transporters | 1 | 2016 | 1 | 0.030 |
Why?
|
Islet Amyloid Polypeptide | 1 | 2016 | 1 | 0.030 |
Why?
|
Arterioles | 1 | 2016 | 14 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2004 | 332 | 0.030 |
Why?
|
Databases, Bibliographic | 1 | 2016 | 12 | 0.030 |
Why?
|
England | 1 | 2016 | 14 | 0.030 |
Why?
|
DNA Primers | 2 | 2010 | 54 | 0.030 |
Why?
|
Weight Loss | 1 | 1997 | 101 | 0.030 |
Why?
|
Diet Records | 1 | 2016 | 7 | 0.030 |
Why?
|
Arterial Pressure | 1 | 2016 | 14 | 0.030 |
Why?
|
Genes, Recessive | 1 | 2015 | 6 | 0.030 |
Why?
|
Indiana | 1 | 2015 | 17 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 232 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2015 | 16 | 0.030 |
Why?
|
Cross-Linking Reagents | 1 | 2015 | 17 | 0.030 |
Why?
|
Datasets as Topic | 1 | 2015 | 4 | 0.030 |
Why?
|
Acetamides | 1 | 2015 | 7 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2015 | 13 | 0.030 |
Why?
|
Diet Surveys | 1 | 2015 | 18 | 0.030 |
Why?
|
Polysomnography | 1 | 2015 | 94 | 0.030 |
Why?
|
Pyridines | 1 | 2015 | 45 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2015 | 8 | 0.030 |
Why?
|
Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 3 | 0.030 |
Why?
|
Scotland | 1 | 2015 | 7 | 0.030 |
Why?
|
Sacrum | 1 | 2015 | 27 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2015 | 23 | 0.030 |
Why?
|
Sulfotransferases | 1 | 2014 | 6 | 0.030 |
Why?
|
Transcription Initiation Site | 1 | 2014 | 3 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2015 | 25 | 0.030 |
Why?
|
beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.030 |
Why?
|
Phosphatidylserines | 1 | 2014 | 7 | 0.030 |
Why?
|
Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2014 | 43 | 0.030 |
Why?
|
Receptors, Kainic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2014 | 2 | 0.030 |
Why?
|
Forkhead Box Protein O3 | 1 | 2014 | 6 | 0.030 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2014 | 5 | 0.030 |
Why?
|
Phonetics | 1 | 2014 | 10 | 0.030 |
Why?
|
Galanin | 1 | 2014 | 4 | 0.030 |
Why?
|
Autoantigens | 1 | 2014 | 39 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 364 | 0.030 |
Why?
|
Occupations | 2 | 2005 | 15 | 0.030 |
Why?
|
Basal Ganglia Diseases | 2 | 1991 | 11 | 0.030 |
Why?
|
Sulfonylurea Compounds | 1 | 2014 | 4 | 0.030 |
Why?
|
Life Expectancy | 1 | 2014 | 19 | 0.030 |
Why?
|
Phagosomes | 1 | 2014 | 3 | 0.030 |
Why?
|
Databases as Topic | 1 | 2014 | 19 | 0.030 |
Why?
|
Dominican Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
New York | 1 | 2014 | 10 | 0.030 |
Why?
|
Glutamates | 2 | 2011 | 17 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2014 | 58 | 0.030 |
Why?
|
Injections, Intraventricular | 1 | 1993 | 13 | 0.030 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 63 | 0.030 |
Why?
|
Autophagy | 1 | 2014 | 30 | 0.030 |
Why?
|
Antigens | 1 | 1993 | 27 | 0.030 |
Why?
|
Circle of Willis | 1 | 2013 | 6 | 0.030 |
Why?
|
Antibody Specificity | 2 | 2004 | 54 | 0.030 |
Why?
|
Sulfites | 1 | 2013 | 1 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2014 | 65 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2013 | 11 | 0.030 |
Why?
|
Patient Compliance | 1 | 2015 | 165 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2014 | 32 | 0.030 |
Why?
|
Electrophysiological Phenomena | 1 | 2013 | 11 | 0.030 |
Why?
|
HLA-D Antigens | 1 | 2013 | 3 | 0.030 |
Why?
|
Dextrans | 1 | 2013 | 6 | 0.030 |
Why?
|
Religion | 1 | 2013 | 40 | 0.030 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2013 | 6 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2013 | 5 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 55 | 0.030 |
Why?
|
Epitopes | 2 | 2004 | 88 | 0.030 |
Why?
|
Serine | 1 | 2013 | 11 | 0.030 |
Why?
|
Trans-Activators | 1 | 2013 | 28 | 0.030 |
Why?
|
Proteoglycans | 1 | 2014 | 345 | 0.030 |
Why?
|
Patch-Clamp Techniques | 1 | 2013 | 115 | 0.030 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2013 | 7 | 0.030 |
Why?
|
Embryonic Stem Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
Chromatography, Gel | 1 | 2012 | 15 | 0.030 |
Why?
|
Electrocardiography | 1 | 2014 | 219 | 0.030 |
Why?
|
Nutrition Assessment | 2 | 2003 | 31 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2013 | 89 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2013 | 111 | 0.030 |
Why?
|
Mutation Rate | 1 | 2012 | 4 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 88 | 0.030 |
Why?
|
Nerve Fibers, Unmyelinated | 1 | 2012 | 4 | 0.030 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2012 | 27 | 0.030 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1992 | 5 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 286 | 0.030 |
Why?
|
Rats, Inbred F344 | 1 | 2012 | 48 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 34 | 0.030 |
Why?
|
Phosphoserine | 1 | 2012 | 5 | 0.030 |
Why?
|
Cerebellar Cortex | 1 | 2012 | 7 | 0.030 |
Why?
|
Dependovirus | 1 | 2012 | 37 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2012 | 63 | 0.030 |
Why?
|
Tissue Plasminogen Activator | 1 | 1992 | 42 | 0.030 |
Why?
|
Pregnancy-Associated Plasma Protein-A | 1 | 2012 | 1 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2012 | 1 | 0.030 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2012 | 2 | 0.030 |
Why?
|
Autoradiography | 1 | 2012 | 11 | 0.030 |
Why?
|
Drug Resistance | 1 | 2012 | 58 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 1992 | 16 | 0.030 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 7 | 1 | 2011 | 3 | 0.030 |
Why?
|
Patient Advocacy | 1 | 1992 | 14 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 1992 | 55 | 0.030 |
Why?
|
Secretory Pathway | 1 | 2011 | 1 | 0.030 |
Why?
|
Clathrin | 1 | 2011 | 3 | 0.030 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2011 | 10 | 0.030 |
Why?
|
Insecticides | 1 | 1991 | 3 | 0.020 |
Why?
|
Cadaver | 1 | 2013 | 362 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 1992 | 59 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2012 | 22 | 0.020 |
Why?
|
Cytoskeleton | 1 | 2011 | 51 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2005 | 456 | 0.020 |
Why?
|
American Heart Association | 1 | 2011 | 29 | 0.020 |
Why?
|
Disks Large Homolog 4 Protein | 1 | 2011 | 5 | 0.020 |
Why?
|
CELF Proteins | 1 | 2011 | 1 | 0.020 |
Why?
|
Cell Membrane | 1 | 2011 | 106 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2011 | 7 | 0.020 |
Why?
|
1,2-Dipalmitoylphosphatidylcholine | 1 | 1991 | 1 | 0.020 |
Why?
|
Dementia, Multi-Infarct | 1 | 1990 | 1 | 0.020 |
Why?
|
Brain Damage, Chronic | 1 | 1990 | 3 | 0.020 |
Why?
|
Phenanthrolines | 1 | 2010 | 4 | 0.020 |
Why?
|
Carbon Radioisotopes | 1 | 2010 | 7 | 0.020 |
Why?
|
Pharmaceutical Preparations | 1 | 1991 | 20 | 0.020 |
Why?
|
Endothelin-Converting Enzymes | 1 | 2010 | 1 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2010 | 60 | 0.020 |
Why?
|
Tissue Banks | 1 | 2010 | 8 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2010 | 13 | 0.020 |
Why?
|
Neurofibrils | 1 | 2010 | 2 | 0.020 |
Why?
|
Valosin Containing Protein | 1 | 2010 | 1 | 0.020 |
Why?
|
Caspase 7 | 1 | 2010 | 2 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 44 | 0.020 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2010 | 40 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 1991 | 92 | 0.020 |
Why?
|
Internet | 1 | 2011 | 90 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2009 | 14 | 0.020 |
Why?
|
Fixatives | 1 | 2009 | 7 | 0.020 |
Why?
|
Perioperative Care | 1 | 2009 | 53 | 0.020 |
Why?
|
Sirtuin 1 | 1 | 2009 | 1 | 0.020 |
Why?
|
Convulsants | 1 | 2008 | 1 | 0.020 |
Why?
|
Deoxyglucose | 1 | 2008 | 5 | 0.020 |
Why?
|
Dactinomycin | 1 | 2008 | 7 | 0.020 |
Why?
|
eIF-2 Kinase | 1 | 2008 | 5 | 0.020 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2008 | 9 | 0.020 |
Why?
|
Nitro Compounds | 1 | 2008 | 10 | 0.020 |
Why?
|
Chromatography, Gas | 1 | 2009 | 12 | 0.020 |
Why?
|
Propionates | 1 | 2008 | 13 | 0.020 |
Why?
|
Antimetabolites | 1 | 2008 | 14 | 0.020 |
Why?
|
Evoked Potentials | 1 | 2008 | 19 | 0.020 |
Why?
|
Tissue Extracts | 1 | 2008 | 14 | 0.020 |
Why?
|
Nervous System Physiological Phenomena | 1 | 1988 | 4 | 0.020 |
Why?
|
Cytosol | 1 | 2008 | 63 | 0.020 |
Why?
|
Respiration | 1 | 1988 | 35 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2012 | 352 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2007 | 19 | 0.020 |
Why?
|
Bromocriptine | 1 | 1987 | 15 | 0.020 |
Why?
|
NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 3 | 0.020 |
Why?
|
Receptors, Neurotransmitter | 1 | 1987 | 6 | 0.020 |
Why?
|
Myoclonus | 1 | 1987 | 34 | 0.020 |
Why?
|
Aspartic Acid | 1 | 1987 | 15 | 0.020 |
Why?
|
Microtubules | 1 | 2007 | 28 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 273 | 0.020 |
Why?
|
Proxy | 1 | 2006 | 2 | 0.020 |
Why?
|
NADPH Dehydrogenase | 1 | 2006 | 7 | 0.020 |
Why?
|
Nitric Oxide Synthase | 1 | 2006 | 47 | 0.020 |
Why?
|
Piperazines | 1 | 1987 | 93 | 0.020 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2005 | 15 | 0.020 |
Why?
|
Drug Synergism | 1 | 2005 | 66 | 0.020 |
Why?
|
Emigration and Immigration | 1 | 2005 | 13 | 0.020 |
Why?
|
Alemtuzumab | 1 | 2005 | 4 | 0.020 |
Why?
|
Vidarabine | 1 | 2005 | 11 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2005 | 10 | 0.020 |
Why?
|
Melphalan | 1 | 2005 | 16 | 0.020 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2005 | 16 | 0.020 |
Why?
|
Fever | 1 | 2005 | 40 | 0.020 |
Why?
|
Administration, Oral | 1 | 2005 | 144 | 0.020 |
Why?
|
Kentucky | 1 | 2005 | 1 | 0.020 |
Why?
|
Remission Induction | 1 | 2005 | 103 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 245 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2005 | 116 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2005 | 47 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2005 | 191 | 0.020 |
Why?
|
src-Family Kinases | 1 | 2004 | 8 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 9 | 0.020 |
Why?
|
Jurkat Cells | 1 | 2004 | 13 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2004 | 32 | 0.020 |
Why?
|
Sick Role | 1 | 2004 | 12 | 0.010 |
Why?
|
Immunoblotting | 1 | 2004 | 52 | 0.010 |
Why?
|
Play and Playthings | 1 | 2003 | 8 | 0.010 |
Why?
|
Censuses | 1 | 2003 | 6 | 0.010 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2003 | 7 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2004 | 103 | 0.010 |
Why?
|
Apoptosis | 1 | 2004 | 259 | 0.010 |
Why?
|
Population | 1 | 2002 | 3 | 0.010 |
Why?
|
Casein Kinases | 1 | 2002 | 2 | 0.010 |
Why?
|
beta Carotene | 1 | 2002 | 7 | 0.010 |
Why?
|
Hypotension | 1 | 2002 | 27 | 0.010 |
Why?
|
Dominance, Cerebral | 1 | 2002 | 23 | 0.010 |
Why?
|
Cholinergic Fibers | 1 | 2002 | 8 | 0.010 |
Why?
|
Arousal | 1 | 2002 | 44 | 0.010 |
Why?
|
Paired-Associate Learning | 1 | 2001 | 4 | 0.010 |
Why?
|
Systole | 1 | 2001 | 20 | 0.010 |
Why?
|
Cell Size | 1 | 2001 | 8 | 0.010 |
Why?
|
Diastole | 1 | 2001 | 36 | 0.010 |
Why?
|
Blood Pressure Determination | 1 | 2001 | 21 | 0.010 |
Why?
|
Thermodynamics | 2 | 1991 | 43 | 0.010 |
Why?
|
Neurobehavioral Manifestations | 1 | 2000 | 1 | 0.010 |
Why?
|
Interview, Psychological | 1 | 2000 | 36 | 0.010 |
Why?
|
Vesicular Acetylcholine Transport Proteins | 1 | 1999 | 1 | 0.010 |
Why?
|
Mitochondrial ADP, ATP Translocases | 1 | 1999 | 1 | 0.010 |
Why?
|
Superoxides | 1 | 1999 | 26 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1999 | 164 | 0.010 |
Why?
|
Treatment Refusal | 1 | 1998 | 13 | 0.010 |
Why?
|
Self Administration | 1 | 1998 | 36 | 0.010 |
Why?
|
Dentate Gyrus | 1 | 1997 | 8 | 0.010 |
Why?
|
Body Height | 1 | 1997 | 33 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 245 | 0.010 |
Why?
|
Caregivers | 1 | 1997 | 144 | 0.010 |
Why?
|
Irritable Mood | 1 | 1991 | 6 | 0.010 |
Why?
|
Psychomotor Agitation | 1 | 1991 | 14 | 0.010 |
Why?
|
Attitude | 1 | 1991 | 29 | 0.010 |
Why?
|
Biological Transport | 1 | 1991 | 44 | 0.010 |
Why?
|
Temperature | 1 | 1991 | 74 | 0.010 |
Why?
|
Cell Membrane Permeability | 1 | 1991 | 59 | 0.010 |
Why?
|
Models, Chemical | 1 | 1991 | 43 | 0.010 |
Why?
|
Radiography | 1 | 1992 | 678 | 0.010 |
Why?
|
Bethanechol | 1 | 1989 | 5 | 0.010 |
Why?
|
N-Methylaspartate | 1 | 1987 | 4 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1987 | 34 | 0.000 |
Why?
|
Cyclic GMP | 1 | 1987 | 11 | 0.000 |
Why?
|
Mice, Inbred DBA | 1 | 1987 | 51 | 0.000 |
Why?
|
Kinetics | 1 | 1987 | 230 | 0.000 |
Why?
|
Seizures | 1 | 1987 | 88 | 0.000 |
Why?
|
Corpus Striatum | 1 | 1987 | 113 | 0.000 |
Why?
|